German-speaking Society of Nephrology and Dutch Society of Nephrology  by unknown
Kidney International, Vol. 28 (1985), pp. 695—712
Abstracts
German-speaking Society of Nephrology
and
Dutch Society of Nephrology
Maastricht, The Netherlands
February 22—23, 1985
Anti-glomerular basement membrane antibodies in human sera: Detec-
tion by a modified micro-ELISA. M. Weber, H. Köhler, M. Manns, P.
Kurz, and K. H. Meyer zum Bflschenfelde. Department of Internal
Medicine, University of Mainz, Mainz, Federal Republic of Germany.
Demonstration of antibodies (AB) against antigens (AG) of glomerular
basement membrane (GBM) is possible by various methods including
indirect immunofluorescence, gel diffusion, passive hemaglutination
and radioimmunoassay. Recently, ELISA techniques have also been
reported. We describe an anti-GBM-AB ELISA with special emphasis
to the choice of microtiter-plates used. Human GBM was prepared
according to Westberg and Michael (1970). A collagenase digest of
GBM (sGBM) was used to coat suitable microtiter-plates. Sera were
added and allowed to react. Bound immunoglobulins were then de-
tected using rabbit anti-hu-IgG-AP. Enzymatic activity was measured
using p-nitrophenyl-phosphate and absorbance was read at 405 nm.
Various sorts of microtiter-plates were tested according to their influ-
ence on assay-sensitivity. Optimal conditions for each step were
determined. Specificity and reproducibility were tested. Anti-GBM-AB
were detected in 11 sera from patients with Goodpasture's syndrome,
but not in sera obtained from patients with other types of glomerulo-
nephritis (52), SLE (18), Sharp-syndrome (4), Wegener's granulomato-
sis (3), primary biliary cirrhosis (15), chronic active hepatitis (20),
rheumatoid arthritis RhF pos. (10) and RhF neg. (10), or healthy blood
donors (178). Moreover, specificity was also demonstrated by absorp-
tion studies. Preincubation of positive sera with sGBM resulted in a
reduction of anti-GBM activity as detected by the ELISA under the
cut-off value of the assay. Sensitivity of the assay was best when using
PVC plates with flat wells. When using other materials (Immulon,
Nunclon-delta, Polystyrene) or wells with U or V forms, AB recogni-
tion was worse. Carbonate-buffer, pH 9.6, proved to be the best coating
buffer. Background-reduction was obtained using Tween and/or BSA in
various steps of the assay or by removing lgG contamination of sGBM
by affinity chromatography. Reproducibility was high. Inter-assay
coefficient of variation ranged from 0.1 to 6%. The intra-assay coeffi-
cient of variation was estimated from 1.4 to 6.1%. The assay proved to
be much more sensitive than the indirect IF method. The ELISA may
be used for the detection of anti-GBM antibodies in sera from patients
and in monitoring titers of circulating AB under therapy. Furthermore,
the ELISA may be helpful in studies aiming at characterization of the
GBM antigens.
Characterization and quantitation of the leucocyte interstitial infiltrate
in acute idiopathic interstitial nephritis (IN). R. Waldherr, K. Andrassy,
and E. Ritz. Departments of Pathology and Medicine, University of
Heidelberg, Heidelberg, Federal Republic of Germany. Renal biopsies
from six patients (4 , 2 9; age 24 to 67 yrs) were examined by
immunohistochemical methods (IF, three layer peroxidase or alkaline
phosphatase technique). In addition to conventional IF (by which
anti-TBM or IC mediated IN could be excluded), various monoclonal
antibodies to leucocyte surface epitopes were used: LC (leucocyte
common antigen), C3b receptor and HLA-Dr (monocytes, B cells),
OKMI (monocytes, null cells), B cells (HD 5,6,12,28,37,39, Pan B),
(natural) killer cells (Leu-7), T cells (OKT3, OKTI I, Lyt 3), and T-cell
subsets (OKT4, OKT8, Leu-2a, Leu-3b). Positive cells were quanti-
tated with an eye-piece graticule (at 400:1) and expressed as cells/0.1
mm2 SEM. The majority of interstitial cells (64 to 94%) were T cells
(83.3 18.9). Monocytes/macrophages constituted 4.2 to 17.2%,
polymorphs, B cells, and (J-chain positive) plasma cells being only a
minor proportion of the total cellular infiltrate. The T helper
(inducer)/cytotoxic (suppressor), that is, OKT4/OKT8 ratio in the
kidney markedly differed from the normal blood ratio (1.9 0.7) since
it was I in 5/6 cases. The predominance of T cytotoxic/suppressor
cells in the interstitial infiltrate underlines the pathogenic role of this T
subset in the mediation of renal injury in IN.
Genetic polymorphism of C3 and Bf in mesangial IgA glomerulonephri-
tis (IgA-GN). M. Rambausek, A. W. L. van De Wall Bake, R.
Schumacher, R. Spitzenberg, U. Rother, L. A. Van Es, and E. Ritz.
Medizinische University Klinik and Department of Immunology,
Heidelberg, FRG, and Academisch Ziekenhuis, Leiden, The Nether-
lands. The involvement of complement in the pathogenesis of IgA-GN
is poorly understood. IgA or IgA-IC do not activate Cl but trigger the
alternative pathway. C3 plays a key role in the glomerular events
leading to inflammation; an important regulator in its activation is
protein Bf. Polymorphism of both C3 and Bf, as recognized with
electrophoretic technique, is under genetic control. The most frequent
phenotypes are S and F. In this report, we present our results regarding
the frequencies of C3 and Bf alleles in lgA-GN as compared with
patients with non IgA-GN and controls, obtained from the local
population.
IgA-GN(N = 45)
Non-LgA-GN(N = 67)
Control
(N = 65)
C3FF 8.9%* 7.5% 3.4%
C3FS 17.8%* 41.8% 35.8%
C3SS 733%* 50.7% 60.8%
BIFF 8.9%* 1.5% 2.0%
BfFS 37.8% 40.3% 38.0%
BfSS 533%* 58.2% 60.0%
* P < 0.01control vs. IgA-GN; Fisher's exact test.
The results suggest: 1) increased prevalence of homozygous pheno-
types (C3FF); and 2) an increased prevalence of BfFF in IgA-GN.
Preliminary data suggest that BfFF is associated with a poorer progno-
sis.
Immunocytochemical examination of matrix component produced by
mesangial cells in vitro. R. B. Sterzel, D. H. Lovett, H. G. Foellmer, D.
Biemesderfer, and M. Kashgarian. VA Medical Center, Yale University
School of Medicine, New Haven, Connecticut, USA. To examine the
capability of mesangial cells (MC) to produce extracellular matrix, we
conducted an in vitro study on primary cultures of rat MC. MC were
obtained from isolated glomeruli of young rats and maintained up to 12
weeks in medium containing 20% fetal calf serum [J Immunol 130:1796,
1983]. MC outgrowth showed a characteristic organization consisting of
bands of elongated or stellate intertwined cells. After confluency at 10
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to 16 days, MC continued to grow in irregular multilayers. As demon-
strated microscopically, MC produced extracellular matrix material
within 2 to 3 days after plating, and large amounts of matrix accumu-
lated with time. By 2 to 3 weeks, focal MC proliferation, matrix
secretion, and necrotic cell debris produced nodular protrusions which
gradually formed large hillocks. immunocytochemistry of MC out-
growth was performed on culture plates or on sectioned material using
specific rabbit polyclonal or mouse monoclonal antibodies to isolated
matrix proteins and FITC-conjugated, affinity-purified second antibod-
ies. Within 3 days of culture, MC elaborated fibronectin and collagens
I, IV and V. With time, strands of matrix, notably in the central mass
of hillocks stained more extensively for these constituents. Staining for
larninin was less pronounced. Collagen Ill was not detected. Myosin
was regularly found in distinct intracellular fibrils and in the extracel-
lular material of hillocks. Similar staining was observed for the out-
growth of bovine smooth muscle cells, serving as controls. Rat skin
fibroblasts revealed no or faint staining for myosin, collagen IV and V.
The results show that proliferating MC can be maintained in homoge-
nous culture for a prolonged time period. MC produce large amounts of
extracellular proteins found in normal glomeruli and known to accumu-
late in the mesangial matrix of diseased glomeruli. MC hillocks, formed
in vitro, resemble somewhat the nodular changes of the mesangium in
certain glomerular diseases. We conclude that the in vitro model of
prolonged MC outgrowth may be of use for more quantitative analysis
of the synthesis of mesangial matrix components. Effects of defined
inflammatory or metabolic stimuli could also be explored.
Antigenic targets involved in antibody-mediated membranous glomer-
ulonephritis in mouse and rat. K. J. M. Assman, P. Ronco, M. M.
Tangelder, W. P. J. Lange, P. Verroust, and R. A. P. Koene.
Departments of Pathology and Nephrology, Sint Radboud Hospital,
University of Nzjmegen, Njjmegen, The Netherlands, and the Institut
National de Ia Sante et de Ia Recherche Médicale, Unite de Recherche
de Nephrologique Normale et Pathologique, Hopital Tenon, Paris,
France. Injection of heterologous antiserum in the mouse directed
against murine, pronase-digested renal tubular antigens (TAPron) re-
sults in a membranous glomerulonephritis. Although the antiserum
contains antibodies against the Heymann antigen (gp-330), as evidenced
by its binding pattern in rat glomeruli, this is not the target in the mouse
because the Heymann antigen is not present in the mouse glomerulus.
The glomerular damage in the mouse is initiated by binding of another
antibody population to an antigen (gp-90) present in a homogeneous
distribution on the visceral epithelial cells of the mouse and to a lesser
degree of the rat. We have not studied the organ distribution of these
two antigens by indirect immunofluorescence. Antibody to gp-330 was
eluted from kidneys of rats previously injected with anti-mouse TAPron
serum. Antibody to gp-90 was eluted from livers of similarly injected
mice because this organ expresses gp-90, while lacking gp-330. Immu-
noprecipitation studies confirmed that the rat eluate detected only the
gp-330 antigen, while the mouse eluate reacted with gp-90, but not with
gp-90. Antigen gp-330 was found to be present in lung, epididymis,
visceral yolk sac, several gland epithelia, ovary, oviduct, and uterus.
Antigen gp-90 had a more widespread distribution that closely resem-
bled the organ localization of some peptidases. The most prominent site
was the capillary endothelium of many organs. The results show that an
antigen with a molecular weight and an organ distribution different from
the Heymann antigen can serve as a target for antibody-mediated
membranous glomerulonephritis.
The regulation of the autoimmune response in active Heymann's
nephritis by T-cell subsets in Lewis rats. E. de Heer, M. R. Daha, and L.
A. van Es, University Hospital, Nephrology Department, Leiden, The
Netherlands. In this study, the cellular regulation of active Heymann's
nephritis (HN) was investigated, an experimental autoimmune nephrop-
athy in rats. Using an enzyme-linked short-term culture assay, we
measured autoantibody production in vitro by lymphoid cells directed
against the purified nephritogenic renal tubular epithehial glycoprotein
(RTE-Gp). By this method, we showed that only the lymph nodes that
drain the site of immunization contained autoreactive B cells. Pretreat-
ment with cyclosporine A (Cy-A) or with multiple injections of high
doses of antigen in Freund's incomplete adjuvant markedly inhibited
the development of disease to a subsequent nephritogenic challenge, In
challenged high dose tolerant (HDT) rats, the autoimmune response
was only 5 to 10% of immunized non-tolerant animals. This tolerance
could not be transferred by lymphoid cells from Cy-A treated rats, but
could be transferred by lymphoid cells derived from the thymus or
spleen of HDT rats. Transfer of affinity-column fractionated splenic T
cils from HDT rats demonstrated that 0X8 helper enhanced and
0X8' suppressor T cells suppressed the autoimmune response in
subsequently challenged recipients. This study shows that a single shot
induction of HN results in a local abrogation of autoimmune tolerance,
while this tolerance appears to be maintained in the other compartments
of the immune system. Furthermore, the above-mentioned transfer
experiments indicate that both 0X8 helper and OX8 suppressor T
lymphocytes are involved in the induction and suppression, respec-
tively, of the autoimmune response in this experimental nephropathy.
Cell proliferation In anti-GBM glomerulonephritis in the mouse. A. R.
Morley and J. Wheeler. Department of Pathology, University of
Newcastle upon Tyne, United Kingdom. Crescentic ghomerulonephri-
tis, regardless of etiology, carries a poor prognosis. The classical
hypothesis of formation by epithelial (capsular) cell proliferation has
been modified in recent years by the demonstration of macrophages/
monocytes in experimental and human studies. The work of Sterzel and
Pabst suggests that cell kinetic studies are of value in determining the
extent to which cell proliferation determines crescentic development. A
model has been developed which is suitable for such studies. T 70
(beige) mice were pre-immunized with rabbit lgG followed by immuni-
zation with rabbit anti-mouse glomerular basement membrane anti-
body. The dose of antibody was found to be critical. A single intra-
venous injection of 0.1 ml antibody had no effect, whereas four
intravenous injections of 0.1 ml antibody produced edema, ascites, and
proteinuria within 13 days of the last antibody injetion. At autopsy,
renal and pulmonary hemorrhage was present. Linear IgG deposits and
crescent formation were seen. Fibrin was deposited in glomerular
capillary loops and in afferent arterioles. Quantitative studies revealed
significant increases in capsular cell numbers and mean glomerular area
doubled in the 13 days of the experiment. Native mitotic index rose to
0.8% by 6 days. An increased dose of 0.8 ml of anti-GBM antibody in
four injections produced similar findings, but within 6 days of the final
injection. With this protocol, initial weights and ages of the mice were
important factors in the severity and mortality of the disease. Vincris-
tine stathmokinetic studies on capsular cells suggested a potential cell
cycle time of approximately 250 hr. Mitotic activity was also seen in the
glomerular tuft of up to 0.9%, but distinction between endothelial cells
and monocytes was not possible. The role of cell proliferation in
crescent formation will be discussed.
Modulation by cyclosporin A (CyA) of toxin-induced autoimmune
reactions and glomerulonephritis in the brown Norway (BN) rat. B.
Prummel, J. Aten, C. Bosman, A. M. vd. Wal, Ph. J. Hoedemaeker,
and J. J. Weening. Department of Pathology, State University Leiden,
Leiden, The Netherlands, Upon exposure to low doses mercuric
chloride, the BN rat develops a transient autoimmune syndrome
characterized by lymphadenopathy, splenomegaly, mucositis, hyper-
gammaglobuhinemia, autoantibodies to DNA and basemene menbranes,
and glomerulonephritis with massive proteinuria. This syndrome is
genetically restricted and has been shown to be associated with
alterations in B- and T-lymphocyte cooperation, resulting in polyclonal
B cell stimulation. In this model, the effect of CyA on the induction and
severity of the lesions has been studied, since CyA has been shown to
affect T helper cell function and has been suggested to be of value in the
treatment of autoimmune disease in humans. Four groups of 5 female
BN rats were studied. Two groups (A and C) received HgCI2 alone (I
mg per kg s.c. at alternate days), two groups (B and D) received HgCl2
and, in addition, CyA (20 mg per kg s.c. daily). Groups A and B were
treated for 8 days, and were then used to study changes in lymphoid
organs (thymus, lymphnodes, spleen) by lightmicroscopy (LM) and
immunohistochemistry (IHC). Groups C and D were treated for 14
days, and were followed for a total duration of 40 days. During that
time, the development of anti-glomerular basement membrane (GBM)
antibodies was quantified by an ELISA technique, and proteinuria was
measured daily. At sacrifice, glomerular lesions were studied by LM
and LHC. Marked changes present in thymus, lymph node, and spleen
of all animals of group A at day 8 (weight increase, architectural
changes, loss of T cells) were completely abrogated in group B by CyA.
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At day 40, no overt changes were noted in lymphoid organs of animals
of groups C and D. Circulating anti-GBM antibodies were found in
non-CyA treated animals of group C as early as day 4. The values
(Mean sD) increased from 0 at day 0 to 195 137 at day 8 and to a
maximum of 510 73 at day 15. In the CyA treated group D, anti-GBM
antibodies could only be measured in part of the animals and showed a
maximum value of 57 40 at day 14. Urinary protein loss developed in
animals of group C at day 12, reached a maximum value of 431 242mg
between day 14 and 21, and had disappeared at day 24. No proteinuria
developed in CyA treated animals of group D. LHC showed linear
deposits of rat IgG along the GBM in all animals of group C (4 +) and
of group D (2 +). C3 could not be detected, and at LM, glomeruli
showed no alterations. In conclusion, CyA suppresses mercury-i-
nduced autoimmune phenomena and prevents clinically overt glomer-
ulonephritis in the BN rat. Upon which cellular mechanism (for
example, diminished la-expression, suppression of interleukin 2, or
inhibition of cytotoxic T cells) this effect of CyA is based, remains to be
established.
Effect of parathyroid hormone and calcium intake on cAMP-concen-
tration in specific brain areas of spontaneously hypertensive rats. H.
Geiger, G. Schmid, K. Keil, and A. Heidland. Department of Nephrol-
ogy, Medical Clinic, University of Wuerzburg, Wuerzburg, Federal
Republic of Germany. Altered catecholamine (SAAVEDRA J,
GROBECKER H, AXELROD J) and cAMP content (SCHMID G et al) have
been observed in specific brain areas of SHR. Recent investigations
allude to a potential participation of calcium status and parathyroid
hormone activity on the pathogenesis of high blood pressure. The
mechanisms, in particular with regard to central blood pressure regu-
lation, are still unknown. For this reason, we examined the influence of
parathyroidectomy and different calcium diets on the cAMP concentra-
tion in specific brain areas. Methods: Four-week-old male SHR re-
ceived a calcium deficient (0.5% Ca) or a high calcium diet (5% Ca).
Half of them underwent parathyreoidectomy (PTX). Four groups were
studied: 1) PTX-SHR with low Ca diet (PTX-l Ca); 2) sham-operated
SHR with low Ca diet (SO-I Ca); 3) PTX-SHR with high Ca (PTX-h Ca);
4) sham-operated SHR with high Ca diet (SO-h Ca). After a 4-week
treatment period, the animals were sacrificed by means of a focused
microwave irradiation of the brain. The different nuclei were removed
by the micro-punch technique (Palkovits M.). Cyclic AMP was mea-
sured radioimmunologically. Results: Initial serum calcium averaged
3.00 0.16 mmole/liter. After 4 weeks, there were significant differ-
ences between PTX-l Ca (2.31 0.32) and SO-i Ca (2.78 0.38) (P <
0.002); PTX-l Ca and PTX-h Ca (3.92 0.33) (P < 0.001); SO-I Ca and
cAMP concentration in specific brain areas
Cortex Cortex Nucleus Amyg- Hippo-
cinguli parietalis caudatus dala campus
PTX - I CaSO-ICa
PTX - h CaSO-hCa
PTX — I Ca
PTX - h Ca
SO - I Ca
SO—hCa
P< 0.05 — — P< 0.01
P<0,0l — — —
P<0.05 P<0.05 — — P<0.05
P<0.05 — — P<0.05
cAMP concentration in specific brain areas
NTS
Central A2-cell A1-cell Locus
grey group group coeruleus
PTX - I CaSO-ICa
PTX - h Ca
SO — h Ca
PTX - I Ca
PTX - h Ca
SO - 1 Ca
SO-hCa
P < 0.05— — —
P<0.05 — — —
P<0.Ol — — P<0.OOl
P< 0.01 — P< 0.001
SO-h Ca (3.98 0.70) (P < 0.002). Initial blood pressure was 112 8
mm Hg. After 4 weeks, PTX-l Ca (130 17) was significantly lower (P
<0.002) than PTX-l Ca (157 12 mm Hg). Different calcium diet and
parathyroidectomy levels did not cause significant changes of cAMP
content in A I-cell group, candate nucleus, and Amygdalae. But, there
were significant alterations of cAMP in cortical areas (parietal cortex,
Cingulate cortex, hippocampus), in midbrain structures (central grey),
in catecholaminergic cell groups in medulla oblongata (nucleus tractus
solitarii with A 2-cell group), and, in particular, locus coeruleus.
Discussion: PTX with low calcium diet was followed by a significant
change in five specific brain areas, which are in close connection with
central blood pressure regulation. It is assumed that central mecha-
nisms participate in the attenuated time course of hypertension in SHR
fed with high calcium diet. The catecholaminergic locus coeruleus may
play an important role under this condition, which supports previous
investigations about the calcium calmodulin dependence of adenylcy-
clase in this brain area (Schmid et al, 1984).
Acute and long-term changes in free intracellular calcium after
nifedipine in patients with essential hypertension. H. Hailer, T. Lenz, M.
Ludersdorf, A. Distler, and Th. Philipp. Medizinische Klinik und
Poliklinik, Klinikum Stegiitz, Berlin, Federal Republic of Germany.
Recent reports have shown a decrease in intracellular calcium after
long-term treatment with calcium antagonists, 13-receptor blockers and
diuretics. The aim of the present study was to investigate short-term
changes in intracellular calcium levels after acute lowering of blood
pressure with calcium antagonists. We studied ten previously untreated
patients with essential hypertension (WHO stage I-Il). After 30 mm in
a supine position, the patients received 20 mg nifedipine (N) sI. Before
and 60 mm after application of N, blood was drawn for measur ments
of platelet cytosolic calcium. After 6 weeks of treatment with N (2 x 20
mg/day), the changes in blood pressure and intracellular calcium were
investigated again. Cytosolic calcium was measured using the calcium-
sensitive indicator, quin 2. N lowered blood pressure from 169/103 to
141/92 mm Hg (P 0.01) within 60 mm. Free intracellular calcium
decreased from 122.2 21.4 to 92.4 7.1 nmoles (P 0.05). At the end
of the treatment, blood pressure was 147/96 mm Hg and basal cytosolic
calcium 108.2 7.6 nmoles before acute administration of N. 60 mm
after N, blood pressure fell to 140/91 mm Hg and intracellular calcium
to 98 6.9 nmoles. We conclude that the acute and long-term blood
pressure-lowering effect of N is accompanied by a fall in free cytosolic
calcium. The most pronounced effect was seen in patients with high
intracellular calcium levels originally. After long-term treatment, the
acute changes are reduced. We could not find, however, a correlation
between blood pressure before therapy and the cytosolic calcium, or
between the alterations of both parameters. In some patients, despite
blood pressure decrease, no fall in cytosolic calcium was found,
suggesting further antihypertensive mechanisms of N.
Blood pressure control in pregnant rabbits: Vasopressor and
prostaglandin interactions. A. J. M. Donker, P. Barone, and R. Venuto,
Departments of Medicine, Free University, Amsterdam, The Nether-
lands, and State University of New York at Buffalo, Buffalo, New York,
USA. The relationship between angiotensin 11(A11), norepinephrine
(NE), and prostaglandins in the regulation of systemic blood pressure
was examined in conscious rabbits. The arterial prostaglandin E2
(PGE2) concentration was higher in pregnant than in nonpregnant
rabbits. Resting blood pressure was slightly lower in gravid animals.
The pressor response to incremental doses of A11 or NE was blunted in
the pregnant rabbits. Volume loading by saline infusion did not change
the relative refractoriness of pregnant rabbits to the pressor response of
A11, although plasma renin activity had fallen. Meclofenamate, a
cycloxygenase inhibitor, failed to alter the resting blood pressure in
either group of animals, although it reduced PGE2 levels more than 60%
in the pregnant animals. The pressor response to A11 or NE was
significantly increased only in the pregnant rabbits when the A11 or NE
infusion was repeated following meclofenamate. Pregnant rabbits could
also be differentiated from nonpregnant by their higher peripheral blood
levels of renin and NE, and their uniform marked hypotensive response
to converting enzyme inhibition (captopril) or a-adrenergic blockade
(phentolamine). These results add support to the concept that increased
levels of A11 and NE are necessary to counteract the effect of circulating
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PGE2 that is increased ten-fold during rabbits' gestation, and probably
originates from the uretero-placental complex.
Long-term study of the sympathetic nervous system and the renin-
angiotensin system in borderline hypertension. R. Bähm, M. v. Baak, M.
v. Hooff, J. v. Kemenade, and K. H. Rahn. Departments ofMedicine
and Pharmacology, University of Limburg, Maastricht, The Nether-
lands, Borderline hypertension (BH) often is considered to be an early
phase of essential hypertension. A long-term study of the sympathetic
nervous system and the renin-angiotensin system in BH could give
insight into the role these systems play in the development of hyper-
tensive disease. Therefore, in 24 male normotensive subjects (NS,
standing blood pressure < 125/85 mm Hg at three measurements within
2 weeks, age 18 to 30 years) and in 26 borderline hypertensives (BHT,
blood pressure 140/90 to < 160/100 mm Hg), plasma catecholamine
levels and plasma renin activity (PRA) were measured repeatedly at rest
and during bicycle ergometry during an observation period of 6 years.
Plasma catecholamine concentrations were measured radiometrically.
At the beginning of the study, the plasma noradrenaline concentration
during supine rest was 0.37 0.04 ng/ml in NS. This parameter rose to
1.21 0.10 ng/ml during bicycle ergometry, corresponding to 75% of
maximum work load (75% MWL). The noradrenaline concentrations
measured in BHT did not differ from these values (P> 0.3). The same
was true for plasma adrenaline. PRA in NS was 1.21 0.20 ng A 1/mI/hr
during supine rest and 2.06 0.34 ng A I/mI/hr during physical activity
at 75% MWL. The values measured in BHT did not differ from these
data (P > 0.3). During the observation period of 6 years, standing blood
pressure rose to levels higher than 160/100 mm Hg in three BHT (group
1). At the beginning of the study, group I had resting blood pressure
values comparable with those measured in the other BHT (group 2).
However, group I had somewhat higher blood pressure values (214
9/104 5mm Hg) than group 2(193 3/88 3mm Hg) during physical
exercise (75% MWL). During the observation period, blood pressure
did not rise in group 2 nor in all NS. At the end of the observation
period, there were no differences in plasma catecholamine concentra-
tions and in PRA between NS and group 2 (P > 0.2). In group I, plasma
catecholamine levels were not altered. However, there was an increase
of PRA from 0.74 0.39 to 1.95 0.57 ng A I/mI/hr. The study
demonstrates that only in a small percentage of subjects with BH, blood
pressure has a tendency to rise. The results do not support the
assumption of increased sympathetic activity in BH.
The intrinsic sympathomimetic activity of beta-adrenoceptor blockers
is not beta-adrenoceptor subtype selective. A. E. Daul, X. L. Wang, and
O.-E. Brodde. Medizinische Klinik and Polik!inik, Division of Renal and
Hypertensive Diseases, University of Essen, Essen, Federal Republic
of Germany. The intrinsic sympathomimetic activity (ISA) seems to
play an important role in beta-adrenoceptor blocker-induced modula-
tion of beta-adrenoceptor density and responsiveness. To further char-
acterize the ISA, we studied the effects of beta-adrenoceptor blockers
with and without ISA on beta-2 adrenoceptor density (assessed by
'25iodocyanopindolol binding) in lymphocytes of 34 normotensive vol-
unteers aged 20 to 35 years. The ISA was determined on spontaneously
beating right atria from reserpinized rats (ISA isoprenaline = 1.0).
Propranolol (unselective; no ISA; 4 x 40 mg/day for 8 days) induced an
25% increase in lymphocyte beta-2 adrenoceptor density, which still
persisted 3 days after withdrawal. The beta-l selective blocker
bisoprolol (no ISA; K0 beta-2/K0 beta 1= 102; 1 x 10 mg/day),
however, did not affect beta-2 adrenoceptor density. In contrast,
pindolol (ISA = 0.39; unselective; 2 x 5 mg/day) decreased lymphocyte
beta-2 adrenoceptor density by about 50%; after withdrawal, beta-2
adrenoceptor density after 4 days was still significantly reduced. Similar
effects were obtained with the beta-I selective blocker celiprolol (ISA =
0.32; K0 beta-2/K0 beta-I = 37; 1 x 200 mg/day): it reduced beta-2
adrenoceptor density by 25% after 2 days and by 35% after 8 days.
Since the positive chronotropic effect of beta-adrenoceptor blockers
with ISA on rat atria is mediated by beta-I adrenoceptor stimulation
and, on the other hand, the beta-l selective blocker celiprolol with ISA
decreased beta-2 adrenoceptor density in lymphocytes, it is concluded,
that the ISA of beta-adrenoceptor blockers is not beta-adrenoceptor
subtype selective.
Continuous 24-hr hemodynamic monitoring during the onset of the
antihypertensive effect of pindolol and propranolol. A. v.d. Meiracker, A.
J. Man in 't Veld, H. J. Ritsema van Eck, F. Boomsma, F. H. M.
Derkx, G. J. Wenting, and M. A. D. H. Schalekamp. Department of
Medicine 1, Erasmus University, Rotterdam, The Netherlands. Com-
parison of the hemodynamic effects of pindolol (PIN), a beta-blocker
with partial agonistic activity (PAA), and propranolol (PRO), which is
devoid of PAA, may help to clarify the mechanism of the
antihypertensive action of beta-blockade. Initially, a fall in mean
arterial pressure (MAP) after blockade of cardiac beta-receptors with
PRO is completely offset by baroreflex-mediated vasoconstriction.
PIN, with sufficient PAA to maintain cardiac output (CI) and heart rate
(HR) at rest, may therefore lower MAP more rapidly than PRO. To test
this hypothesis, we investigated the onset of the antihypertensive effect
of PIN, 10 mg b.i.d., and PRO, 80 mg t.i.d., for 24 hr in two groups of
10 patients with essential hypertension. During the study, patients had
complete bedrest. MAP and HR were measured with the invasive
Oxford system. CI and pulmonary artery pressure (MPAP) were
measured by means of a flow-directed triple lumen Swan-Ganz
thermodilution catheter.
Results
MAP HR
mm Hg hpm
PIN PRO PIN PRO
CI
I min' m2
PIN PRO
Baseline
2-hr%
4-hr%
l2-hr%
24-hri%
118 120 64
—l +5
+7
+9
+14
63
—9"
—2
—3
+2
2.84 2.72
+2
+16 —10
+21 —5
+16" —3
TPRI
dyne s cm5
MPAP
mm Hg
PIN PRO PIN PRO
Baseline
2-hr i%
4-hr%
l2-hr%
24-hr%
3304 3543
5
25b —8
19b —2
—14
13 12
+3
+6 +15"
—I ÷19b
—4 +2
Baseline: Mean values; P <0.05; "P <0.01; P < 0.001 (differences
from baseline).
Plasma noradrenaline (PNA) did not change on PIN and rose by 18% (P
<0.05) 2 hr after PRO. Active plasma renin (APR) decreased by 38% (P
< 0.01) and 59% (P < 0.001) after PIN and PRO, respectively. No
correlation was found between MAP and APR during PRO, whereas
these parameters were inversely correlated during PIN (r = 0.58, P <
0.001). Conclusions: I. The maximum fall in MAP after PIN and PRO
is seen after 4 and 24 hrs, respectively. This difference may be related
to the initial vasoconstrictor response after PRO, which is absent after
PIN. 2. After 24 hrs, the fall in MAP on PIN and PRO is similar,
although on PIN it is associated with reduced total peripheral resistance
(TPRI), whereas on PRO it is caused by reductions in CI and TPRI.
Therefore, TPRI is lower on PIN than on PRO. 3. MPAP did not change
on PIN, but it rose on PRO. This suggests that PIN did not exert a
negative inotropic effect, which may be related to its PAA. 4. The
vasodilatation after PIN and PRO cannot be explained by reduced APR.
5. The absence of a rise in PNA during vasodilatation after PIN and
PRO suggests that blockade of central and/or peripheral presynaptic
beta-receptors underlies these phenomena.
A comparative study of myocardial function in normotensive
hemodlalysls patients (HD) and healthy volunteers. H. Schneider, W.
Hahn, D. Hoppe, and J. Vlachojannis. St. Markus Hospital,
Frankfurt/Main, Federal Republic of Germany. The existence of a
specific uremic cardiomyopathy has been frequently discussed. Echo-
cardiographic studies have revealed an impaired ventricular function in
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HD patients compared to normal subjects. There is only a small number
of reports on invasive investigations of cardiac performance in HD
patients. The object of the present study was to obtain data on left
ventricular function from measurements of pulmonary arterial pressure
(PA). The study was performed on 41 normotensive HD patients with a
mean age of 46.5 15.5 years, and a mean duration of dialysis of 21.4
20.8 months (group 1). Forty-four normotensive healthy subjects
with a mean age of 44.1 13.6 years (group 2) served as controls. In
both groups, the heart rate (HR), the systemic pressure (RR), as well as
the mean pulmonary arterial pressure (PX) were measured at rest, as
well as under exercise of I watt per kg body wt under treadmill exercise
in a supine position. The cardiac output (CO), as well as the stroke
volume index (SW) at rest, according to the method of Fick, were
measured in addition (see Table).
Group
At rest
RR
N HR systolic
RR —
diastolic PA Hb
1
2
41 77.2 133.8
9.5 17.0
44 72.8 131.5
8.7 15.5
P NS NS
83.8 11.1
11.7 2.8
84.3 11.2
9.9 2.9
NS NS
8.3
1.7
14.8
1.4
<0.001
Group
At rest
CO SVI HR
Under exercise
RR RR
systolic diastolic PA
I
2
7.5 58.3 119.5
1.6 13.9 13.6
6.3 46.3 120.6
1.4 9.9 14.6
<0.001 <0.001 NS
183.0 86.3
20.7 11.6
170.5 90.6
21.4 11.4
<0.01 NS
24.5
6.7
22.9
6.5
NS
A significant difference between the two groups with regard to the PA
at rest and under exercise could not be found. The HR at rest, as well
as the exercise-induced diastolic RR, differed markedly in the two
groups, although the difference did not reach the significant level of 1%.
Systolic RR under exercise was significantly higher in the HD patients
(P < 0.01). The CO and the SVI was, as expected, significantly higher
in group I than in group 2. These results do not support the assumption
of a specific uremic cardiodepressive factor.
Effects of enalapril on sodium balance in hypertension. G. J. Navis, P.
E. de Jong, A. J. M. Donker, G. K. van der Hem, and D. de Zeeuw.
Department of Nephroiogy, State University Hospital Groningen,
Groningen, The Netherlands. ACE-inhibitors have natriuretic proper-
ties in human hypertension. To what extent Na balance is influenced
by continued treatment, and whether the effect on Na excretion
depends on the pre-existing state of Na balance is not well defined.
We, therefore, studied the effect of 7 days of treatment with enalapril 10
mg b.i.d. on Na balance in six patients with essential hypertension in
balance on a diet with 50 mmoles Na/24 hrs. In five of these patients,
the study was repeated on a Na intake of 200 mmoles Na/24 hrs, after
a washout period of 3 weeks. All medication was stopped 4 weeks prior
to the study. 24-hr urine collections were made continuously during a
run-in period of 7 days and during the week of treatment. Renal function
was measured by the clearance of '31I-hippuran and '251-iothalamate
prior to and after 7 days of treatment. Initial PRA was lower at the 200
mmoles period. Withdrawal of enalapril led to a Na balance positive
by 117 (42 to 180)b mmoles 7 days after the 50 mmoles treatment period(N = 6) and positive by 137 (85 to 180) mmoles 7 days after the 200
rnmoles period (N = 4). No effect on K balance was observed either
at institution or at withdrawal of enalapril. We conclude that enalapril
induces a negative Na balance, both at a liberal and a restricted Na
intake. The magnitude of the Na loss is similar on both intakes. It may
be that a diuretic effect of enalapril contributes to its antihypertensive
effects.
Pre-
treatment Day 1 Day 7
Na intake, 50 mmoles (N = 6)
95' 92bMAP, mm 108
Hg (105 to 110) (87 to 104) (87 to 97)
Body wt, 74.2 739 725b
kg (64.0 to 92.3) (63.7 to 91.6) (63.1 to 90.6)
24-hr Na 40 77 49
excretion (30 to 51) (41 to 103) (36 to 52)
Cumulative —
Na bal- (—11 to —71) (—71 to —232)
ance,
mmoles
ERPF, 421 — 447
mi/mini (328 to 666) (377 to 661)
1.73 m2
GFR, 117 — 119
mi/mini (103 to 138) (107 to 134)
1.73 m2
Na intake, 200 mmoles (N = 5)
98a 95bMAP, mm 106
Hg (101 to 113) (89 to 112) (90 to 102)
Body wt, 75.3 75.0 749a
kg (62.7 to 90.3) (62.4 to 89.1) (61.9 to 88.9)
24-hr Na' 205 241 233
excretion (197 to 247) (185 to 290) (213 to 263)
Cumulative — —23
Na bal- (+15 to —79) (—63 to —194)
ance,
mmoies
ERPF, 448 — 440
mi/mini (355 to 569) (339 to 604)
1.73 m2
GFR, 121 — l14
mi/mini (Ill to 137) (109 to 137)
1.73 m
a P < 0.05
b P < 0.01. Paired Student t test vs. initial value.
Transplant renal artery stenosis: Results of surgical repair. J.H. van
Bockei, R. van Schiifgaarde, A. van Es, L. C. Paul, and G. G. Perszjn.
Departments of Surgery and Nephroiogy, University Hospital Leiden
and Eurotranspiant Foundation, Leiden, The Netherlands. Hyperten-
sion in renal allograft patients can be caused or contributed to by many
factors. One of these is severe transplant renal artery stenosis (TRAS).
The fact that TRAS can be observed both in the absence and presence
of post-transplant hypertension prevents the applicability of strict rules
in the clinical management of TRAS. In addition, algorithms used for
diagnosing renovascular hypertension in non-transplanted individuals
are known to be unreliable in renal allograft recipients. This study
describes results obtained with the surgical management of TRAS in
combination with hypertension in the recipients of the first 500 renal
allogralts at our institution. In 53 (11%), TRAS was angiographically
shown to be present (at least 50% reduction of diameter). Surgical
repair was performed in 30/53 (57%). Of these 30 patients, 22 had a short
and circumscript (Type 1) and eight a long segmental (Type II) stenosis.
Operative deaths did not occur. Clinical results were better with Type
I than Type II: graft loss was 0/22 vs. 2/8 (25%); a residual stenosis was
observed in 3/22 (14%) vs. 4/8 (50%); and hypertension responded
favorably in 9/22 (45%) vs. 2/8 (25%). In half of those patients with
persisting hypertension after technically successful vascular repair, a
spontaneous improvement was observed in the course of 2 to 3 yrs after
surgery. The same observation was made in the medically treated
patients. A detailed analysis of factors, such as pre-transplant hyper-
tension, presence or absence of native kidneys, rejection episodes, and
immunosuppressants, could not account for the differential results nor
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contribute to more accurately defining pre-operatively the contribution
of TRAS to post-transplant hypertension. The 5-yr actuarial graft
survival was similar in surgically (82%) and medically (83%) treated
patients. We conclude that clinical considerations in combination with
the angiographical type of TRAS are predominant factors for choosing
the optimal mode of treatment.
Steroid-induced adrenal suppression: A risk factor for kidney graft
rejection? H. A. Bock, F. P. Brunner, J. J. Staub, and G. Thiel.
Department Innere Medizin, Kantonsspital, Base!, Switzerland. In our
current therapy protocol for kidney transplants (cyclosporine + low-
dose prednisone), the single morning dose of prednisone is slowly
tapered from 0.5 mglkg/day to either 0.1 mg/kg/day (in second trans-
plants or whenever creatinine stays above 200 LM/liter or none.
Rejection episodes are treated with 0.5 g i.v. methylprednisolone
pulses. Since we occasionally observed rejection episodes at the time of
reducing prednisone below 0.1 mg/kg/day (the equivalent of average
endogenous glucocorticoid production), we prospectively monitored
adrenal function by performing an ACTH-test (0.25 mg Synacthen® iv.
between 7 and 9 A.M.) in every patient once he had been on 0.1
mg/kg/day prednisone for 2 weeks. The test was considered as "sup-
pressed", if plasma cortisol (RIA) prior to ACTH was < 200 nM/liter, or
did not rise above 550 nM/liter 60 mm after ACTH. Symptoms of
adrenal insufficiency were screened by a questionnaire and a visual
analogue scale. We present the results of an evaluation 120 days after
the ACTH test (x SEM):
ACTH Test
Normal Suppressed P value
Total patients 17 13
First:second
transplants 16:1 7:6 P < 0.05
Mean steroid dose until
test, mg/kg/day 0.5 0.l 0.6 0.1 NS
Mean CyA dose until
test, mg/kg/day 7.0 0.4 6.6 0.5 NS
Days from
transplantation to
ACTH test 176 32 l70 26 NS
Creatinine on day of
ACTH test,
cmoles/liter 150 13 176 15 NS
Creatinine on day 120
after ACTH test,
jcmoles/liter 159 14 201 22 P < 0.05
Rejections/patient
before ACTH test 1.5 0.4 1.6 0.4 NS
Rejections/patient after
ACTH test 0.6 0.2 0.6 0.2 NS
Thus, there was evidence of adrenal suppression in some 45% of
patients, particularly frequent in second transplants. Clinical symptoms
of adrenal suppression were minimal or absent. However, the group
with suppressed adrenal function developed significantly decreased
graft function 120 days after the ACTH test. This difference could not
be explained by clinical rejection episodes and occurred in spite of a
frequently continuing therapy with low doses of steroids. We conclude
that there is a substantial group of patients who are prone to develop
adrenal suppression under low-dose steroids, and who seem at risk to
develop impaired graft function. This could occur as a result of
subclinical rejection during infection or in the second half of the day,
which is not "covered" by prednisone taken in the morning. Withdraw-
ing steroids in these patients might be particularly important for
long-term outcome (although hazardous), as continuing steroid therapy
could maintain this mechanism.
Cytolytic antibody (CyAb) responses to human cytomegalovirus (CMV)
during active CMV infection in renal allograft recipients: Possible conse-
quences for the selection of hyperimmune anti-CMV globulin. J. M.
Middeldorp, A. M. Tegzess, and T. H. The. Department of Clinical
Immunology and the Rena! Transplantation Unit, University Hospital,
Groningen, The Netherlands. In view of the recent interest in the use of
hyperimmune globulin for prophylaxis and treatment of CMV infection
in immune-compromised patients, we present the results of a longitu-
dinal study on the development of humoral immunity in renal allograft
recipients, with special reference to the CyAb responses directed
against cytomegalovirus-membrane antigens exposed on the surface of
the infected cell (CMV-MA). A total of 41 allograft recipients with
clinical and serological evidence of active primary (N = 14) or second-
ary CMV infection (N = 27) were monitored (bi)weekly before and
during (0 to 8 weeks) active CMV infection and monthly until I year
thereafter. Clinical, virological, and serological data were obtained:
routine CMV serology (1gM and lgG) was done by ELISA; 1gM and lgG
against CM V-MA by membrane fluorescence and cytolytic antibodies
by a 51Cr-release assay. Antibody (1gM and IgG) against CMV-LA
(ELISA) was diagnostic and preceded complement binding by several
weeks. CyAb developed early (0 to 3 weeks) after onset of clinical
symptoms, and reached highest levels in patients with secondary CMV
infection. Recovery from CMV infection in most cases was related to
the development of CyAb, and, in a few cases, fatal CMV infection was
associated with a total absence of CyAb, whereas EL1SA antibodies
were present in normal levels (no antibody collapse). In the group of
allograft recipients with secondary but not primary CMV infection, high
CyAb responders (> 25% specific release) had a better graft function 1
year post Tx (P < 0.05, x2 test). Further analysis revealed that CyAb
can be of the IgG class, and, in fact, high levels of cytolytic IgG were
detected. CyAb activity is mainly directed against the late membrane
antigen complex, and is not related to antibodies against intracellular
CMV antigens or neutralizing antibodies, as measured in most serolog-
ical studies. CyAb were only found during acute and convalescent
phase of CMV infection, and were not detectable in sera from control
blood donors (N = 75) without active CMV infection (P < 0.001,
Wilcoxon rank sum test). Our data suggest that the CyAb response is
directed against an individual set of CMV antigens and may be
important in recovery from CMV infection. Selection of sera with CyAb
activity against CMV-infected target cells may be an important
criterium in the preparation of hyperimmune globulin, which may be of
use for prophylaxis and treatment of CMV infection in the immune-
compromised host.
Kidney transplantation in patients with diabetic nephropathy. A. J.
Hoitsma, J. F. M. Wetzels, J. H. M. Berden, and R. A. P. Koene.
Department of Medicine, Division of Nephrology, St. Radboud Hospi-
tal, Nijmegen, The Netherlands. In a retrospective study, we analyzed
the outcome and complications after renal transplantation in 30 patients
with diabetic nephropathy. The results were compared with those of
427 non-diabetic patients transplanted in the same period. The mean age
of diabetic and non-diabetic patients at transplantation was not different
(40 vs. 36 years). The mean interval between the onset of diabetes and
the start of renal replacement therapy was 24 years. One year graft and
patient survivals were 60% and 85%, respectively. This was signifi-
cantly lower than the survivals in non-diabetic patients (74 and 94%).
There were no differences in serum creatinine levels between both
groups, not even after 4 years' follow-up. However, proteinuria was
significantly heavier in diabetics and increased with time, suggestive of
recurrence of the original disease in the transplant. Apart from a larger
number of superficial wound infections, the incidence of infections was
not higher in the diabetic recipients. Amputations continued to be a
major problem in these patients. Twenty-four percent of the recipients
had to undergo one or more amputations, mainly at the lower extrem-
ities. All these patients were males and smokers, and all but one had
excellent renal function. Despite these complications, the results of
renal transplantation in diabetics was good enough to consider it as the
best treatment available for patients with diabetic renal failure.
Is the intake of initially high doses of cyclosporine A in cadaveric kidney
transplantation justified? Results of a randomized study. W. Niebel, U.
Krause, K. H. Albrecht, R. Windeck, H.-D. Jakubowski, and F. W.
Eig!er. University Clinics of Essen, Essen, Federal Republic of Ger-
many. Because of the likely dose-caused nephrotoxicity of cyclosporine
A (CsA), it is particularly important in cadaveric kidney transplantation
to give CsA in as low a dosage as possible to reduce nephrotoxicity
considerably, but also to provide optimal immunosuppression. The
present study investigates the effectiveness of low levels of CsA in
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blood. Since the first of December, 1983, all kidney recipients have
received CsA in a randomized manner, that for the first 4 weeks (time
of hospitalization) two separate therapeutic groups were treated with
two different dosage levels of CsA (blood levels of 100 ng/ml, RIA
measured): I) group A, N = 48, higher dosage level, mean 500 ng/ml, 2)
group B, N = 52, lower dosage level, mean 250 ng/ml. 1. The actuarial
one-year graft survival rate was 80% in the lower CsA levels (group B),
and, therefore, had a tendency to be better than the one with the higher
CsA levels, 73% in group A. 2. Surprisingly, clinically and/or histolog-
ically proven rejections occurred in 40% of patients with high CsA
levels, but only in 21% of patients with low levels. 3. The primary
function rate in both groups is about 30 to 40%. In both groups, organ
losses because of irreversible rejection were seen in five patients. 4. In
group A, a serum creatinine concentration of 2 mg% was reached after
13 weeks, whereas in group B, it was reached after only 8 weeks. 5. If
at higher or lower CsA dosage, blood levels of less than 100 ng/ml were
reached, then one would have to assume that symptoms of a classical
rejection were occurring. In the early postoperative phase after
cadavenc kidney transplantation, CsA should be so prescribed that the
CsA blood levels are between 200 and 300 ng/ml. These levels are just
as suppressive, but clearly less nephrotoxic, than the higher CsA levels.
Cyclosporin dosage in kidney transplant patients based on body weight
or Broca weight. F. Keller and G. Offerman. Klinikum Steglitz,
Medizinische Klinik, Berlin, Federal Republic of Germany. Variability
of cyclosporin blood concentrations may in part be due to the fact that
cyclosporin dosage is usually based on body weight, which does not
reflect the true tissue distribution of the drug, especially in overhy-
drated and obese patients. Therefore, 27 kidney graft recipients were
investigated retrospectively during the first 13 weeks after transplanta-
tion. Cyclosporin was given in two divided doses (15 mg/kg/day) during
the first 2 weeks and reduced individually thereafter according to blood
levels. Blood samples were drawn at weekly intervals 12 hrs after the
last dosage and hemolyzed by freezing at —20°C. Cyclosporin concen-
tration in whole blood was determined by the Sandoz radio-
immunoassay kit, with an interassay variation coefficient of 11% (N =
13) at therapeutic blood levels (200 to 1000 ng/ml). In each patient, the
lean body mass was determined by K-40 body counter, and the Broca
weight was derived from the patient's height (Broca weight = height —
100). The mean weekly value of cyclosporin dosage decreased from the
2nd to the 13th week by about one-half (from 15 to 7mg/kg/day), as did
also the mean weekly cyclosporin levels (from 1600 to 600 ng/ml), and
a linear correlation (N = 12, r = 0.9468, P < 0.00 1) was found between
dose and blood concentrations (concentration = 219 + 95 dose). Inter-
and intraindividual variability of cyclosporin blood levels could be
explained to 25% by relative overdosage or underdosage according to
the Broca weight, and, in the 2nd week, cyclosporin concentrations
correlated to the dosage based on Broca weight (N = 17, r = 0.8392, P
< 0.001) better than to body weight or lean body mass. Conclusion:
Cyclosporin dosage should be based on Broca weight, not on body
weight.
Increased incidence of thromboembolic complications in cyclosporine A
(CsA) treated cadaveric kidney allograft recipients. Y. Vanrenterghem,
S. de Rave, L. Roels, T. Lerut, A. Baert, J. Vermylen, and P.
Michielsen. U. Z. Gasthuisberg, K. U. Leuven, Leuven, Belgium. A
higher incidence of thromboembolic complications in CsA-treated
patients has until now not been mentioned. In 90 consecutive cadaveric
renal allograft recipients transplanted between February, 1983, and
September, 1984, and treated with CsA and low doses of steroids, we
observed 16 thromboembolic accidents. Pulmonary embolism was
diagnosed in ten patients: in one of them, the diagnosis was made on
necropsy; in the other nine patients, the diagnosis was based on clinical
findings and confirmed by pathologic lung scintigraphy and/or arteriog-
raphy. In two of these ten patients, a deep vein thrombosis was also
present. In three patients, hemorrhoidal thrombosis was seen, and in
two of them, surgical incision was needed. In one patient, thrombosis of
the renal vein was diagnosed on the second postoperative day. In
contrast, in a control group of 90 consecutive patients transplanted
between August, 1980, and January, 1983, and treated with conven-
tional immunosuppression, we found only one episode of superficial
vein thrombosis secondary to anti-lymphocyte globulin administration.
No other thromboembolic complications were seen within the first
posttransplant year. As there were no differences between both groups
for other known risk factors for thromboembolism, we conclude that
the higher incidence of thromboembolic complications in our CsA-
treated patients is related to CsA therapy.
Dermatologic side effects of immunosuppression after renal transplan-
tation: Cyclosporin A versus conventional therapy. H. Kopsa. P.
Schmidt,J. Zazgornik, P. Balcke, and J. Thurner. First Medical Clinic,
Second Dermatologic Clinic, University of Vienna, Vienna, Austria.
One-hundred-seven cases were observed for dermatologic findings after
successful transplantation. In group I, immunosuppressive therapy
consisted of corticosteroids and azathioprine in 66 patients with 84
grafts. The observation time ranged from 1 to 48 months. In group II, 41
recipients received low-dose steroid therapy and cyclosporin A for I to
28 months. Treatment of acute rejection was methylprednisolone in
both groups. Dermatologic check-up was routinely done at 3-month
intervals. Clinical investigation was completed by viral, bacterial, and
mycotic tests and skin biopsy. Results: Viralcutaneous infections were
seen in 72% of group I, but only in 42% of group II. The frequency of
mycotic dermatologic infections, mainly due to candida albicans, tri-
chophyton, and epidermophyton, was 61% in group I and 28% in group
11. Comparison of bacterial infection of the skin between the two groups
revealed a striking decrease from 54% to 11%. Non-infectious
dermatologic complications of skin, nails, hair, and gingiva were
evident in 84% of group land 91% of group II. In cyclosporin A-treated
recipients, no premalignant or malignant skin lesions were observed. As
a side effect of cyclosporin A, hirsutism occurred in 75% 4 to 6 weeks
after onset of medication. Gingival hyperplasia was seen in 34%. Both
complications decreased with dose reduction of cyclosporin A. Con-
clusion: The use of cyclosporin A after renal transplantation leads to a
remarkable decrease of infectious skin disorders. Non-infectious cuta-
neous disorders, however, are revealed more frequently because of
hirsutism and hyperplasia of the gingiva.
Mixed IgAiIgG cryoglobulinemia with rapid progressive glomerulone-
phritis (RPGN). M. Weber, H. KOhier, J. Fries, and K,-H. Meyer zum
Buschenfelde. Department of Internal Medicine and Institute of Pa-
thology, University of Mainz, Mainz, Federal Republic of Germany.
Mixed cryoglobulins may present with a typical clinical syndrome
thought to be due to immune complex-like deposition of the cold
insoluble proteins. Only a few cases of IgA/IgG cryoglobulinemia have
been reported; none associated with RPGN. A 48-year-old man was
admitted to the hospital in 1982. Eight years previously, diagnosis of
ankylosing spondylitis was established. Four months prior to admis-
sion, he noticed fatigue and arthralgia. Laboratory data revealed an
ESR of 141 mm nW, but otherwise normal data. On examination, he
had fever, crural edema, dyspnoe, and diarrhea. The serum creatinine
was 12.9 mg%. A serum cryoglobulin was found composed of mono-
clonal IgAl-kappa and polyclonal IgG. After separation of the cryo-
components by affinity chromatography, cross mixing studies demon-
strated that the cryo-IgA exerts antiglobulin activity against human
IgG. Renal biopsy revealed intra-extracapillar glomerulonephntis of the
immune complex-type with crescent formation. One glomerulus exhib-
ited obstructing protein precipitates in the capillary 1oops. Im-
munofluorescence studies revealed diffuse subendothelial deposits
along the glomerular capillary 1oops and the arteriolar vessel walls,
which stained positive for IgA/IgG and C3. A skin biopsy demonstrated
leukocytoclastic angiitis with granular deposits of lgA, IgG, and C3.
Treatment consisting of a combination of intermittent
hemodialysis/plasmapheresis (PP) and administration of immunosup-
pressive drugs (ID) was sufficient in removing the cryoglobulins from
the serum. This was paralleled by clinical improvement and a fall of
serum creatinine to 2.8 mg%. After finishing PP and reduction of the ID,
fever recurred and cryoglobulins again were detectable. An increase in
drug doses and reinstitution of PP could control the cryoglobulinemia a
second time, but the patient developed sepsis and died. A possible role
of the cryoglobulins in the development of the RPGN is suggested by
the corresponding composition of the circulating cryoglobulins and the
immunoglobulins deposited in the kidneys, by the demonstration of
occlusing intraglomerular protein thrombi similar to those seen in
IgM/IgG cryoglobulinemia and by the fact that removal of the
cryoglobulins by PP and ID was paralleled by a dramatic improvement
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in renal function. We believe that IgA/IgG cryoglobulinemia has to be
considered as an autoimmune form of RPGN.
Mercuric chloride-induced autoimmune glomerulopathy in Balb/c
mice. G. J. Fleuren, E. de Heer, J. v. Burgers, C. Osnabrugge, and Ph.
J. Hoedemaeker. Departments of Pathology and Internal Medicine,
State University, Leiden, The Netherlands. Mercuric chloride
glomerulopathy was induced in 50 female Balb/c mice to study the
development of autoantibodies to renal antigens and subsequently of
glomerulopathy. The animals received thrice weekly subcutaneous
injections of 0.02 mg HgCl2, and groups of mice were sacrificed every
other day during the first 4 weeks and subsequently at 5 and 12 weeks
after the first disease-inducing injection. Immunofluorescence demon-
strated mesangial deposits from the second week on. Twelve weeks
after the first injection of mercuric chloride, immune aggregates were
preferentially localized along the glomerular basement menbrane. Elec-
tron microscopy revealed small subepithelial deposits. In the serum of
diseased mice, autoantibodies could be demonstrated directed against
renal tubular epithelial antigens from the second week on, which were
still present 12 weeks after the start of the induction of the disease.
Purification of the autoantigen involved, using SDS-PAGE analysis,
revealed several similarities with RTE-Gp, the autoantigen that is
responsible for the induction of Heymann's nephritis in the rat [Immu-
nology 52:743, 1984]. Cross reactivity between the rat and mouse
autoantibody was demonstrated by ELISA. Western blotting, however,
showed that autoantibodies from mouse sera recognized only one
subcomponent of RTE-Gp. This type of mercuric chloride-induced
nephritogenic immune response in mice is of special interest to the
study of the dysregulation of the immune system leading to autoimmune
disease since most of our knowledge concerning immune regulation is
originally derived from studies in this species. Furthermore, many
inbred congenic mice strains are available with known haplotypes,
which will enable a study of the genetic background of this type of
dysregulation of autoimmune tolerance.
Anti-GBM nephritls In the mouse: Severe proteinuria in the heterolo-
gous phase. K. J. M. Assmann, M. M. Tangelder, W. P. J. Lange, G.
Schrz)ver, and R. A. P. Koene. Departments of Pathology and Medi-
cine, Sint Radboud Hospital, University of Nmegen, Nmegen, The
Netherlands. One of the first experimental models in which immuno-
logic pathways of glomerular injury were studied was the anti-glomer-
ular basement membrane (GBM) nephritis. The disease has been most
extensively studied in the rabbit and the rat because the lesions induced
in these species proved to be highly reproducible. In mice, it was
difficult to induce lesions in the heterologous phase, while the changes
in the autologous phase were not very reproducible. We have induced
a highly reproducible anti-GBM nephritis in the mouse after a single
injection of rabbit or goat antibodies against purified homologous GBM.
Albuminuria was closely related to the amount of antibody given. With
doses of 4 mg or more, low serum albumin concentrations, sometimes
accompanied by ascites and edema, were observed after I week.
Glomerular injury was characterized by an initial accumulation of
polymorphonuclear granulocytes followed by thrombosis and necrosis,
the extent of which defined the outcome of the glomerulonephritis. With
high doses of antibody, the exsudative lesions entered a chronic phase,
while at doses lower than 2 mg, remission of the lesions occurred.
Immunofluorescence studies showed prompt linear fixation of the
injected antibodies to the glomerular capillary wall, accompanied by
immediate binding of C3 in a fine granular pattern. Binding of C3 was
transient. Fibrin deposits appeared at 2 hrs in some glomeruli, increased
thereafter, and were present after I day in more than 90% of the
glomeruli in mice that received 4 mg of antibody. This new, reproduc-
ible model in the mouse is suited for the study of the relationship
between activation of mediator systems, histologic lesions, and protein-
uria.
Characterization of crescent-forming cells in rapidly progressive gb-
merulonephritis (RPGN). G. A. Muller, L. Hofmann, and T. Risler.
Medical University Clinics, Tubingen, Federal Republic of Germany.
In different forms of RPGN, crescents are the histological hallmarks in
the renal biopsy investigated by light microscopy. Cellular components
of crescents may play a major role in the pathogenesis of RPGN and
thus their characterization may give a further insight into the
pathomechanism of RPGN. Therefore, frozen sections of renal biopsy
specimens obtained from ten patients with RPGN type II were inves-
tigated by the immunoperoxidase technique, with selected monoclonal
antibodies against determinants specific for glomerular visceral (TN 10)
or parietal (TN8, TN9) epithelial cells, HLA-D region (TU34, TU39),
T-cells (ClonabT4, OKT8, Lyt3, TU11), granulocytes (TU9), and
monocytes (TMI, TM2, TM3, LeuM3). In all renal biopsy specimens,
only 3 to 5% of the crescent-forming cells belonged to the T/B cell
lineage and about 6% were granulocytes. Ten to 55% of the crescent
cells showed a variable staining with TM2, TM3, and LeuM3, but most
of these cells were negative with TM I, which labeled different
monocyte/macrophage subsets surrounding Bowman's capsule of dis-
eased glomeruli. Only 10 to 25% of these different monocyte/macro-
phage subsets within crescents expressed HLA-D region products as
surface marker. Destruction or displacement of visceral and parietal
epithelial glomerular cells was demonstrated by staining with TN8,
TN9, and TNIO. Nevertheless, about 40% of the cellular constituents
within crescents could still not be characterized by the used monoclonal
antibodies. Besides the various monocyte/macrophage subsets identi-
fied in crescents, further proliferating cells of still unknown origin may
play an important role in the development of RPGN.
Sex and age as determinants of immunologically mediated glomerular
Inflammatory disease. A. Tiebosch, H. Wolters, W. Grave, J. Mooy, Th.
van de Wiel, B. Zeppenfeldt, H. van Rie, and P. van Breda Vriesman.
Departments of Immunology, Pathology, and Internal Medicine, State
University of Limburg, Maastricht, and Departments of Internal Med-
icine, St. Laurentius Hospital, Roermond, Hospital De GoddelUke
Voorzienigheid, Sittard, and De Wever Hospital, Heerlen, The Neth-
erlands. The effect of sex and age on the incidence of glomerular,
immunologically mediated inflammatory disease in adults was exam-
ined in an epidemiological study in the southern part of the province of
Limburg, The Netherlands. In the period 1978 to 1983, 274 renal biopsy
specimens were taken from adults 12 years of age and older because of
persistent or recurrent hematuria (less than I g urinary protein loss
daily), hematuria and proteinuria, isolated persistent proteinuria (more
than I but less than 5 g urinary protein loss daily, in the absence of
Bence Jones proteinuria), nephrotic syndrome (more than 5 g urinary
protein excretion), or uremia (serum creatinine exceeding 300
mmoles/liter). Immunologically mediated (defined as characteristic dep-
osition of Ig and C) gbomerular inflammatory disease constituted 80% of
all gbomerular inflammatory lesions (40% of all renal biopsy specimens).
Sex and age were important determinants. The SLE nephritis (inci-
dence: 4.9 per million inhabitants, annually), anti-GBM nephritis (inci-
dence: 2.5 per million inhabitants, annually), and the minimal lesion
nephrotic syndrome (incidence: 7.3 per million inhabitants, annually)
occurred predominantly in women, with female to male ratios of 5:1,
3:1, and 3:1, respectively. The ratio of female to male in non-immun-
ologically mediated renal disease was 1:2. Primary IgA nephropathy
(incidence: 14.1 per million inhabitants, annually), membranous
nephropathy (incidence: 9.8 per million inhabitants, annually), and
non-anti-GBM extracapillary glomerulonephritis (incidence: 4.2 per
million inhabitants, annually) were mainly found in men, with female to
male ratios of 1:5, 3:8, and 1:9, respectively. The severity of the
glomerular inflammatory changes in males was directly related to age.
In the primary glomerular inflammatory disease, the mild proliferative
lesions occurred in younger males and the extracapillary inflammatory
lesions mainly in older males. Also, within one clinical pathological
entity (primary IgA nephropathy with hematuria), the glomerular in-
flammatory lesions were determined by the age of onset of disease and
not by duration of known hematuria. These results suggest first that
epidemiologically minimal lesion nephropathy belongs to the autoim-
mune renal diseases in adults. Second, they show that, in males, the
severity of the glomerular inflammatory changes in primary glomerular
disease is dependent on the age of onset of disease.
The influence of blood pressure status on progression of renal failure in
IgA-glomerubonephritis (IgA-GN). M. Rambausek, R. Waldherr, K.
Andrassy, and E. Ritz. Departments of Internal Medicine and Pathol-
ogy, Heidelberg, Federal Republic of Germany. Available data under-
score the importance of hypertension (HT) for progression of renal
failure in diabetic nephropathy. Little information is available on the
interrelation of HT and renal function in other glomerular diseases. In
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the present study, we examined the relation between HT and clinical
findings at entry and subsequent deterioration of renal function in 75
patients with biopsy-proven IgA-ON. Overall prevalence of HT was
38.7%. Its presence was related to age, renal function, im-
munohistological pattern, and degree of glomerular sclerosis or vascu-
lar lesions. No correlation was found between HT and level of serum
IgA, IgA immune complexes, or IgA skin deposits. During a median
follow-up of 28 months, the median rate of increase of serum creatinine
(or decrease in l/S-crea) in patients with persistent (that is, on all
occasions) HT (RR > 140/90, resting blood pressure, with or without
antihypertensive medications) was significantly greater than in patients
with intermittent HT (persistent: 0.4 mg/dl per 12 months; range 0.7 to
8.6; intermittent: 0.1 mgldl per 12 months; range —1.0 to + 0.9) (P <
0.05). These observations confirm the role of hypertension in mesangial
IgA-glomerulonephritis. Vascular (arteriolar) lesions on renal biopsy
were found not only to be strongly correlated with presence of
hypertension, but to precede it in longitudinal observations.
Immuno-electron microscopy (JEM) in experimental glomerulonephrl-
tis. J. J. Weening, F. A. Prins, A. M. v. d. Wa!, and Ph. 1. Hoedemae-
ker. Department of Pathology, State University, Leiden, The Nether-
lands. A new IEM technique has been applied to study localization and
quantification of glomerular immune reagents in two models of exper-
imental glomerulonephritis: nephrotoxic serum nephritis and Heymann
nephritis. Nephrotoxic rabbit anti-rat-GBM antibodies were adminis-
tered in different doses to male Wistar rats: group A, 0 ml; group B, 0.1
ml; group C, 0.3 ml; group D, 0.6 ml; and group E, 1.2 ml (N = 2 per
group). After 24 hrs, during which time urine was collected to measure
urinary protein loss, kidneys were studied by light and immunofluoresc-
ence (IF) microscopy, and small pieces of kidney cortex were proc-
essed for IEM using a Lowicryl embedding technique, after fixation in
2% paraformaldehyde and after washing extensively in 0.05 M glycine
buffer. Post-embedding incubation with colloidal gold, conjugated goat
anti-rabbit IgG was performed. Of each animal, two grids with three
glomeruli per grid were examined. At least six random photographs of
each grid were taken and studied for the amount of gold label per nm of
glomerular capillary wall (GCW). Total length of GCW counted per
animal, using an X-Y graphic tablet on prints with a magnification of
x 14,400, was 236.094 27.727 nm. The results are summarized in the
table and are compared with semiquantitative IF microscopy using a
grading scale of 0 to 4+ (values are Mean I SD).
IEM
Group
Anti-GBM
antiserum
ml
Proteinuria
mg/24 hrs
IF
0 to 4+
gold
partic!es/
nm GCW
A 0 3± 1 0 0
B 0.1 4 I I .25 4.2 1.9
C 0.3 4± 1 2±0 11.6±3.4
D 0.6 12 2 3 .25 18.7 3.4
E 1.2 560 62 4 0 24.6 4.8
In addition, the passage of rabbit anti-rat FxlA IgG through the
glomerular capillary wall was followed by IF and IEM at 1, 6, and 120
hrs after intravenous injection of 12 mg IgG. By IEM, the rabbit anti-rat
FxIA antibodies can be followed clearly from the capillary lumen via
the endothelial cell surfaces and the subendothelial space through the
lamina densa during the first 6 hrs to their final localization in the
subepithelial space underneath the slit pore membranes at 5 days.
Additional studies showed that this technique is consistently reproduc-
ible in tissue blocks and in thin sections that have been stored for
several months. Our conclusions are that post-embedding IEM using
gold-labeled antisera on Lowicryl-embedded renal tissue is a valuable
and reliable tool to study and to quantify in relative amounts immune
aggregates bound to renal structures.
Experimental antl-TBM Interstitial nephrltis (EaTBM-IN) in rats:
Tubular handling of microproteins and other solutes. W. H. Boesken, E.
Schreiner, C. Stehle, and G. H. Thoenes. Departments of Medicine,
University Hospital, München and Brüderkrankenhaus, Trier, Federal
Republic of Germany, EaTBM-IN was induced in rats by single
immunization with sheep tubular basement membrane to study the
kinetics of micromolecular proteinuria of tubular origin. Small serum
proteins (mole wt. 60,000 daltons and less), filtered readily by the
glomerular membrane and resorbed completely by tubular cells (as
-microglobulin, lysozyme, and so forth), were measured quantita-
tively in daily 24-hr urines during a 4-week period. Sera were taken on
days 0, 9, 12, 16, and 28. Fractional excretion was calculated for the
named microproteins, albumin, and light chains, as well as for sodium,
phosphate, glucose, and creatinine. Additionally, total proteins were
separated according to molecular size using SDS-PAA electrophoresis.
A biphasic proteinuria with an unspecific albumin- and L-chain excre-
tion at days 2 to 4 and a typical tubular proteinuria at days 10 to 16 was
observed. GFR dropped markedly on day 9, recovering to normal at
day 28. Tubular resorption of sodium and phosphate decreased in
parallel to microproteins, while glucosuria occurred on days 12 to 18.
Comparison of the daily microprotein excretion revealed peak values at
different days. In conclusion, tubular proteinuria, as known from
human diseases, is found temporarily in EaTBM-IN in rats, and allows
one to monitor the disease course. Excretion kinetics of different
microproteins favor the concept of a selective tubular microprotein
resorption.
Effects of cyclosporine in murine SLE. J. H. M. Berden, J. F. H. M.
Hagemann, P. Faaber, and T. RU/ce. Department of Nephrology, Sint
Radboudziekenhuis, N(jmegen, The Netherlands. The immunosuppres-
sive properties of cyclosporine A (CyA) in allogeneic organ and bone
marrow transplantation are well established. Reports on CyA treatment
of autoimmune diseases are scanty, however. We studied the influence
of daily oral CyA administration on the development of autoimmune
disease in MRL/Mp-lpr/lpr (MRL/l) male and female and BXSB male
mice. Both strains dIp a fulminant autoimmune disease, very
similar to human SLE, with 50% mortality at 24 weeks due to diffuse
proliferative glomerulonephritis. Treatment with CyA (25 mg/kg body
wt/daily in 0.1 ml olive oil orally) started at 6 weeks of age and was
given until the age of 20 weeks. Control animals received the same
amount of olive oil. There were no differences between treated and
untreated animals of both strains with regard to mortality, anti-DNA
titers at various intervals after start of the treatment, renal function, and
albuminuria at 20 weeks of age. There was, however, a marked
reduction of lymphoproliferation in MRL/I mice. This proliferation of T
helper cells bearing the Lyt I + 23- phenotype is under the control of the
lpr gene. It is concluded that although CyA treatment considerably
uced lymphoproliferation in MRL/I mice, it does not influence the
course of autoimmune disease in this strain nor in BXSB mice.
Characterization of cultured renal parenchymal cells with monoclonal
antibodies (McAbs). S. Hoberg, S. Oehler, L. Hofmann, T. Risler, and
G. A. Muller. Medical University Clinics, Tubingen, Federal Republic
ofGermany. In the pathogenesis of glomerulonephritis, immune mech-
anisms are thought to play an important role. Surface markers on renal
parenchymal cells may act as target cells for cellular and humoral
immune responses. Functional studies with cultured renal parenchymal
cells may lead to a better understanding of these processes. For this
reason, kidney cells were cultured and characterized by different
McAbs detecting determinants on various cell types of the human
nephron. The cells were isolated from decapsulated human kidneys
(tumor-free parts of kidneys and from cadaveric donor kidneys that
were not grafted) applying enzymic digestion with collagenase or
mechanically with stainless steel meshes of different sizes in succession
to achieve a relatively rough separation of glomeruli and tubular cell
fractions. The cells were cultured at 37CC in a humidified atmosphere of
5% CO2 using a specific culture medium consisting of Waymouth/MEM
(Gibco, Europe) supplemented with 10% heat-inactivated fetal calf
serum (FCS), 100 g/ml streptomycin, 100 U/mI penicillin, and l0 M
insulin. The characterization of the isolated cell fractions during a
period of several subcultures was done in indirect immunofluorescent
studies applying McAbs. The results showed that cell fractions isolated
by different techniques reacted with most of the employed McAbs,
detecting epitopes on mesangial and parietal epithelial cells of the
glomeruli and on tubular epithelial cells, except those of the proximal
part indicating the origin of the cultured cells. There was a variable
expression of distinct determinants on the different cell fractions during
the culture period. A further differentiation was possible using McAbs
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against Factor VIII, Vimentin, and Keratin, which revealed that most
of the enzymic-isolated renal cells express epithelial characteristics,
whereas a high percentage of the mechanically isolated cell fraction
express surface markers specific for endothelial cells. For further
functional cell studies, homogeneous cell populations will be estab-
lished by cloning methods following different cell isolation techniques.
lmmunochemical identification of a renal antigen with the monoclonal
antibody (McAb) TN8. S. Oehler, S. Hoberg, L. Hofmann, T. Risler,
and G. A. Muller. Medical University Clinics, Tubingen, Federal
Republic of Germany. Immunological processes play an important role
in the pathogenesis of glomerulonephritis. Renal antigens of the kidney
parenchyma seem to be targets for humoral and cellular immune
responses. These antigens were biochemically characterized to inves-
tigate a correlation between surface markers and function of kidney
cells. The McAb TN8 was used, previously characterized on isolated
kidney cells in culture to detect determinants on glomerular and
different tubular epithelial cells. 35S-methionin radiolabeled membrane
and intracellular proteins of cultured human renal cells were precip-
itated with TN8, which was bound to Staphylococcus aureus bacterias.
The immunoprecipitates were analyzed in a SDS-polyacrylamidgel
according to the molecular weights (MW). It was shown that the McAb
TN8 precipitated two proteins with MW of 120,000 and 30,000 daltons.
The urine of five patients with glomerulonephritis and of three patients
after kidney transplantation were analyzed with TN8. Using the perox-
idase staining in the immunoblot technique, it was possible to identify
TN8-binding proteins in all investigated patients. The MW of these
proteins were between 14,000 and 37,000 daltons. Further analysis with
ELISA techniques were performed using the McAb TN8 and the urine
of patients with glomerulonephritis and after kidney transplantation to
detect early damage of the nephron.
Wegener's granulomatosis: Report of an unusual case. J. Schirmeister,
R. Walter, F. Weiller, B. Lauterwein, andf. Reitinger. Städi. Klinikum
Karlsruhe, Karlsruhe, Federal Republic of Germany. A 36-year-old
female patient with rapidly progressive glomerulonephritis due to
Wegener's granulomatosis is described. The course of disease in this
case makes this report unique in the literature. The patient was
presented with acute renal failure. The histological examination of renal
tissue proved a very severe variant of rapidly progressive glomerulo-
nephritis, Based on the histological statement, an idiopathic process,
Wegener's granulomatosis or Goodpasture's syndrome, were eligible
causes of the renal failure. Considering that there was no involvement
of any other organ and it was lacking of any specific immunopathologi-
cal feature, Wegener's granulomatosis and Goodpasture's syndrome
became out of the question. Hemodialysis was started to counteract the
renal failure. After a period of 14 months, the first extrarenal involve-
ment appeared in the eyes, as a keratoconjunctivis, but this affection
improved by itself. After 6 further months, there was a Wegener's
granulomatosis 'typical cavern' in the lung to be seen on a radiograph,
and the ocular manifestation got worse, so iritis and a very bad visus
could be found. A bioptical investigation of the nasopharyngeal region
showed no pathological findings. Immediate therapy with cyclophos-
phamide (50 mg/day) and prednisone (100 mg/day) caused an improve-
ment of the conditions of eyes and lung. In spite of all therapeutic
measures, the patient died of cardiorespiratoric insufficiency 42 months
after the outbreak of disease and 22 months after the start of the
combined therapy with cyclophosphamide and prednisone. In this
casuistic report, special emphasis is laid on the diagnostic and thera-
peutic problems of a relatively rare clinical picture. The great variety of
organic manifestations and the not significant interpretable alteration of
immunological parameters make Wegener's granulomatosis a difficult
disease to diagnose.
Renal amyloidosis due to gastric plasmozytoma. A case report. W. M.
Evers, K. Glanzer, H. J. Kramer, and F. Kruck. Medizinische Poliklinik
der Universität Bonn, Bonn, Federal Republic of Germany. About 30
cases of plasmozytoma of the stomach have been reported so far. With
respect to the rarity of the localization and difficulties in diagnosis and
treatment of this disease, we report the clinical course of about 18
months of a 58-year-old male patient with a nephrotic syndrome of
unknown origin (proteinuria, 13.8 g/24 hr, endogenous creatinine clear-
ance, 49 mI/mm). The needle biopsy of kidney showed an amyloidosis
with amyloid deposits around the collagenous fibers. Skeleton X-rays
and bone marrow biopsy could exclude a multiple myeloma. Urinalysis
revealed a kappa and lambda paraprotein excretion, whereas there was
no paraprotcinemia. By endoscopy, polyploid submucose tumors of the
stomach were found, which histologically showed the signs of a severe
amyloidosis. Thus, all criteria of a paraprotein-producing
plasmozytoma were fulfilled, although a plasmozytoma could not be
verified histologically. We started the therapy with a radiation series of
the stomach with a total dose of 30 Gy, which was followed by
chemotherapy with melphalan and fluocortolon (according to Alexan-
ian). By this therapy, the renal excretion of protein was markedly
reduced (from 13.8 to 7.25 g/24 hr) and, finally, no paraproteins were
present in the urine. Endogenous creatinine clearance remained un-
changed. A gradual regression of the intragastral tumors and finally a
normal endoscopic picture, as well as a regression of the mucosal
amyloidosis, was observed. The course of this patient confirms the
possible beneficial effect of alkylating substances on the progression of
the renal amyloidosis and the superiority of conservative therapy over
surgical treatment of localized plasmozytoma of the stomach.
Effects of beta 2-receptor blockade on plasma noradrenaline, renin, and
blood pressure. H. H. Vincent, A. J. Manintveld, and M. A. D. H.
Schalekamp. Department of internal Medicine I, University Hospital
Dkzigt, Rotterdam, The Netherlands. Adrenaline may increase
noradrenaline release and amplify the sympathetic influence on blood
pressure through activation of presynaptic /32-receptors. Blockade of
these receptors will then diminish noradrenaline release and thereby
lower blood pressure. To test this hypothesis, we studied the effect of
the /32-selective blocker, IC! 118551 (50 mg t.i.d.) on heart rate
(beats/mm), plasma noradrenaline (pg/mi), renin concentration
(sU/ml), and blood pressure (mm Hg), and on the response of these
parameters to isoprenaline infusion. The effects were compared to
those of propranolol (80 mg t.i.d.) in a double blind placebo-controlled
crossover study of nine untreated patients with essential hypertension.
The patients were resting supine. Results: Within 2 hrs after the first
dose, both drugs caused a fall in heart rate and in plasma renin
concentration. Plasma noradrenaline and blood pressure were un-
changed. After I week, blood pressure had fallen with both drugs; the
fall was greatest with propranolol. Mean SEM values are given in the
table.
IC! 118551
Baseline 2 hrs 1 wk
Heart rate
Noradrenaline
Renin
Intra-artenal
pressure
Systolic
Diastolic
66 3
313 35
22 7
159 5
86 3
60 2*
285 37
13 4*
161 5
89 3
58 3*
269 31
10 3*
148 2*
78 2*
Propranolol
Baseline 2 hrs I wk
Heart rate
Noradrenaline
Renin
Intra-arterial
pressure
Systolic
Diastolic
67 2
228 37
22 7
155 4
84 3
58 3*
285 45
7 2*
155 5
86 2
53 3*
321 50
6 2*
140 5*
72 3*
* P < 0.05.
Graded infusions of isoprenaline (3.5 to 35 ng/kg/min) raised plasma
noradrenaline and renin. After IC! 118551, the rise in renin was blocked
by a dose factor of 2, after propranolol, it was blocked by a dose factor
of 16. The rise in noradrenaline was abolished by both beta-blockers.
Conclusion: The data are compatible with the hypothesis that beta2-
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receptor blockade diminishes noradrenaline relesae, which in turn
causes a fall in renin and blood pressure.
Factors limiting the value of deterndnation of tetrahydro-aldosterone.
glucuronide in the hypertension diagnostic. S. Abdeihamid, S. Lewicka,
P. Vecsei, P. Fiegel, and D. Waib. Deutsche Klinik f. Diagnosfik,
Hypertension and Nephrology Division, Weisbaden and Pharmakolog.
Inst. der Universität Heidelberg, Heidelberg, Federal Republic of
Germany. In previous studies, we showed that the determination of
urinary tetrahydro-aldosterone (3.5/3) -glucuronide (= conjugated
tetrahydro-aldosterone) is of a better value for the diagnosis of primary
hyperaldosteronism than the traditionally used aldosterone-l8-glucuro-
nide ("urine-aldosterone"). However, in few cases, even the excretion
of tetrahydro-aldosterone-glucuronide remained in the normal range.
The causes of this feature were studied: 1. At first, the role of the
unconjugated tetrahydro-aldosterone was investigated. In eight of 192
urine samples in which the unconjugated tetrahydro-aldosterone was
determined, a significant elevation ((30.0 g/24 hr); values in normal
subjects 1.14 0.85 i.g/24 hr (N = 16)) was obtained, accompanied by
normal or even decreased conjugated tetrahydro-aldosterone. In these
cases, the sums of unconjugated and conjugated tetrahydro-aldosterone
revealed to be of a high diagnostic value. The reason of the elevation of
the unconjugated tetrahydro-aldosterone is not yet clear. 2. Another
factor may be the intestinal bacterium flora, which may transform
tetrahydro-aldosterone into 21-deoxytetrahydro-aldosterone (21-
DTHAId) in the course of the enterohepatic circuit. The table shows the
results obtained; the sums of 21-deoxy-tetrahydro-aldosterone and
tetrahydro-aldosterone allowed a better diagnostical clear-cut distinc-
tion than tetrahydro-aldosterone alone.
Control Primary aldosteronism
(N=21) (N= 14)
21-DTHAId 13.1 7.2 (3.5 to 30) 53.8 40.8 (8.8 to 162.5)
TH-Ald 29.9 11.9 (10.0 to 70.0) 100.6 71.7 (56.3 to 245.0)
21-DTHAId
+ THAId 43.0 15.7 (24.1 to 84.0) 168.3 67.2 (84.4 to 392.0)
Does captopril deteriorate renal function in renovascular disease by
postglomerular vasodilatation? G. Schwietzer, C. Laaf3, D. Kampf, V.
Bähr, G. Schultze, M. Molzahn, and A. Distler. Department of Internal
Medicine, Klinikum Steglitz and Klinikum Charlottenburg, Freie
Universiidt Berlin, Federal Republic of Germany. In hypertensive
patients with bilateral renal artery stenosis (RAS) or RAS of a solitary
kidney, reversible decrease of glomerular ifitration rate (GFR) or acute
renal failure has been observed following captopril administration.
Decrease of GFR has been ascribed to preferential efferent vasodilata-
tion. To test this hypothesis, we measured acute changes of mean
arterial pressure (MAP), renal plasma flow (RPF), GFR (single-shot
l23'-PAH and inulin clearances), plasma renin activity (PEA), and
MAP
mm Hg
RPF GFR
mi/mm
TEAS Pre 127 6 248 21 58 5(N = 8) After 110 7* 241 30 49 5*
Without
TEAS Pre 126 5 238 37 60 5(N = 8) After 109 4* 237 37 50 6*
FF
%
PEA PGE2 Excretion
ng/ml/hr pg/mm
TRAS Pre 24 1 16 5 870 228
(N = 8) After 22 3 83 25* 716 227
Without
TEAS Pre 29 4 10 6 1242 367
(N = 8) After 22 3* 93 22* 978 342
* P < 0.01 compared to pre-values.
PGE2 excretion after 50 mg captopril p.o. in posttransplant hyperten-
sives with and without transplant renal artery stenosis (TRAS) during
stimulation of PEA by diuretics. Mean values SCM are shown below:
Conclusions: 1) Acute changes of MAP, RPF, GFR, and PGE2-
excretion were not significantly different between the two groups. 2)
There was no evidence of efferent vasodilatation in patients with TRAS,
FF decreased only in patients without TRAS. 3) The antihypertensive
effect of captopril was not associated with acute changes of PGE2-
excretion. 4) The results do not support the hypothesis of
postglomerular vasodilatation after captopril in patients with TRAS and
high renin state.
Effect of ketanserin on the function of post-ischemic kidneys. M.
Kamphoff, H.-U. Gutsche, R. Zahorsky, and W. Niedermayer. I.
Medizinische Klinik, Abt. Nephrologie, Universität Kiel, Kiel, Federal
Republic of Germany. Improvement of kidney function in patients with
acute renal failure was observed following treatment with ketanserin
(KET), a recently developed serotonin antagonist. To analyze the
pharmacological effect of KET on acutely impaired kidney function,
blood pressure (P), diuresis (Va), '4C-inulin clearance (GFR), urine
osmolality (Osm), and electrolyte excretion were monitored in clear-
ance experiments on rat kidneys before and after 45 mm of ischemia due
to temporary ligation of the left kidney artery. Starting the re-perfusion
period, a priming dose of 0.125 mg KET/kg body wt was applied,
followed by a sustaining dose of 0.25 mg KET/kg/hr. The post-ischemic
clearance period started 90 mm after kidney re-perfusion. Control
experiments were performed on sham-operated as well on ischemic rat
kidneys without KET application. The following results were obtained:
I(N = 15) 11(N= 14)
Sham-
Control operated Control Ischemia
GFR,
pJ/min 813 104 766 87 1079 98 183 55
Part,
mm
Hg 109 5 104 6 116 3104±3
vu,
pJ/min 3.1 0,6 4.3 0.9 2.5 0.3 11.2 1.7
Osm,
mOsml
kg 1159 142 1410 153 739 159 477 40
HI (N = 15)
Control Ischemia + KET
GFR, pJ/min 1099 77 94 21
P, mm Hg 114 4 96 3
V, ui/min 2.6 0.3 5.8 1.3
Osm, mOsm/kg 1775 136 570 51
Mean values Sn.
Temporary ischemia decreased GFR by 85% of control values, KET
administration was followed by further significant impairment. De-
crease of P during KET administration in the post-ischemic period by
18 mm Hg compared to the pre-ischemic period was only 8 mm Hg more
than in the post-ischemic KET-free control. Thus, 50% lower filtration
rates in KET-treated post-ischemic animals were in parallel, although
not caused by the systemic blood pressure alterations alone. In these
experiments, short-term administration of KET after temporary ische-
mia led to further impairment of renal function. Accordingly, one
cannot expect that KET administration is advantageous to renal func-
tion after onset of ischemic ARF. Our results, however, do not exclude
the possibility that renal function might eventually benefit from seroto-
nm antagonism in certain cases of ARF, as reported by others.
Do calcium antagonists have a beneficial effect on post.ischemic acute
renal failure in conscious dogs? K. Wagner, H. -H. Neumayer, M.
Rafeit, V. Achenbach, M. Molzahn, and A. Distler. Free University of
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Berlin, Berlin, Federal Republic of Germany. Calciumchannel blocking
agents may ameliorate norepinephrine-induced acute renal failure
(ARF) in anesthetized animals. In the "clamping" model of ARF,
results are still controversial. We have investigated the effect of
diltiazem (D) in a post-ischemic model of ARF in conscious dogs. An
electromagnetic flow probe and an inflatable pneumatic cuff were
placed around the left renal artery in 19 uninephrectomized beagle dogs
on a high-sodium diet. ARF was induced by inflating the cuff (180 mm)
in the conscious dog. Group A (N = 5) received a continuous infusion
of 0.9% NaCI (7 days), Group B (N = 6) a continuous infusion of 5 g-
kg' min' D (7 days) immediately after deflating of the cuff, whereas
in Group C (N = 7) the diltiazem infusion was started 3 days prior to
ischemia and then also continued for 7 days (combined pre- and
post-treatment).
Before Ischemia
Group
After Ischemia
Day
1 3 7
RBF
mlmin'
GFR,
mlmin'
FEN, %
161 9
133 3
43±3
34 2
100
A
B
C
A
B
C
A
B
C
129
220*
146
6
II
17*
263
232
171*
125
113
100
10
13
19
212
250
95*
120
101
86
10
15
20*
211
112
61*
Mean, SEM, * P < 0.05.
Conclusion: In our model, diltiazem improves the course of post-
ischemic ARF only in the combined treatment group, but not in the
post-treatment group.
Nifedipine in uremia: Chronic effects on blood hormones and metabolic
intermediates. W. Riegel, W. H. Hörl, E. Heidbreder, E. Wernze, and
A. Heidland. Med. Universitatskliniken Freiburg and Wurzburg,
Freiburg, Federal Republic of Germany. Nifedipine has been shown to
be an effective antihypertensive drug. In essential hypertensive pa-
tients, nifedepine causes different changes in blood hormones, for
example, rise of noradrenaline and renin, as well as changes in insulin
levels. In uremic patients many hormonal and metabolic parameters are
altered. The aim of this study was to investigate the role of nifedipine as
a long-term antihypertensive drug and the influence on blood hormones
and metabolic intermediates in patients undergoing regular
hemodialysis treatment (RDT). Fifteen RDT patients with elevated
blood pressure were selected. The dosage of nifedipine was, 2 or 3 times
per day, 20 mg in retard form. The observation time included a washout
period, 10 weeks of treatment, and a 2-week placebo period. Blood was
taken at the beginning, after 3 and 9 weeks of treatment, and after 2
weeks of a placebo period. The antihypertensive effect was maximally
expressed after 4 weeks and lasted over the whole time of treatment.
Heart rate and body weight remained constant. BUN, creatinine, and
potassium showed no change during the whole time of treatment. The
plasma aidosterone level was lowered significantly after 3 weeks,
whereas plasma renin activity did not alter. In contrast to results gained
in patients with essential hypertension, nifedipine caused a significant
fall of the elevated levels of noradrenaline (from 407.1 30.9 to 321.2
27.5 pg/mI) and dopamine (from 102.2 12.0 to 76.9 8.2 pg/mI).
Adrenalin remained constant (37.8 5.3 pg/mI). After 9 weeks of
treatment T3 and T4 showed highest values (1.07 0.07 ng/ml and 6.07
0.42 sg/m1, respectively). Vitamin D3 was elevated during the whole
period of nifedipine administration, and reached the start value when
placebo was given. However, 1 ,25-dihydroxycholecalciferol remained
constant. PTH was elevated 2 weeks after placebo medication, whereas
serum calcium and phosphorus did not change. Nifedipine caused a
significant fall of serum insulin (from 19.9 2.9 to 13.9 1.7 ig/ml) and
glucose (from 102.1 2.6 to 94.9 2.2 mg/dl) levels, without influ-
encing glucagon values. Pyruvate concentration was significantly ele-
vated after 9 weeks of treatment, also /3-hydroxybutyrate and
acetoacetate values. In spite of this, serum cholesterol and triglycerides
remained unchanged. The calcium antagonist, nifedipine, had no neg-
ative effects on carbohydrate or fat metabolism, and may be safely
employed as an antihypertensive drug in RDT patients.
The influence of diltiazem on renal function: Investigations in chroni-
cally instrumented conscious dogs. K. Wagner, H-H. Neumayer, Ch.
Alexander, G. Schulize, M. Molzahn, and A. Distler. Free University
Berlin, Berlin, Federal Republic of Germany. Calcium antagonists are
widely used in the treatment of hypertension and coronary heart
disease. Little experimental data is available on their influence on renal
function. Thus, we evaluated the influence of diltiazem in chronically
instrumented conscious dogs. A right-sided nephrectomy was per-
formed in six female beagle dogs. After eight weeks, an electromagnetic
flow probe was placed around the left renal artery, and a catheter was
inserted in the aorta. After 8 days, the animals received a continuous
24-hr infusion of diltiazem at a dosage of 2.5 to 5.0 to 10.0 sg min'
kg
Control 2.5 5.0 10.0
g mi,r' kg-I
BPm, mm Hg 120 2.8 110* 108* 105*
GFR,mlmin' 54 6.9 39 41 38
RBF, m1 min' 151 17.5 170 153 123
RVR 0.8 0.65 0.75 0.85
Renin, ng AT1 3.5 1.1 3.8 5.4 75*
Mean, SEM, * P < 0.05.
The results demonstrated that diltiazem led to a dose-dependent de-
crease in BPm. There was an increse in RBF with smaller doses of
diltiazem. Higher doses led to a decrease in RBF and an increase of
PRA. GFR was diminished with all doses of diltiazem,
Effect of antihypertensive treatment with the calcium entry blockers,
nifedipine and verapamil, on alpha receptor density and function. A.
Kribben, E. Fritschka, J. Hoyer, L. Schudrowitsch, A. Distler, and Th.
Philipp. Department Internal Medicine, Klinikum Steglitz, Free Uni-
versity, Berlin, Federal Republic of Germany. We studied the influence
of nifedipine (N) and of verapamil (V) on density and function of
a-receptors, since we have shown that the antihypertensive effect of N
but not of V is accompanied by a reduction of noradrenaline (NA)
reactivity. Reactivity to NA (N = 24), a2-receptors of platelet mem-
branes (3H-yohimbine binding, N = 23) and adenylate cyclase (AC)
activity (PgE1-stimulated, N = 16) were examined in patients with
essential hypertension before and 60 mm after N (20 mg s.l., N = 17)or
120 mm after V (160 mg p.o., N = 10). In addition, we examined
whether the reduction of reactivity to NA might be due to selective a-
or a2-adrenergic effect by comparing the pressor effect of NA with that
of phenylephnne (PH, N = 9). Despite a comparable antihypertensive
effect, all parameters of a-receptor density and function, as well as NA
reactivity, decreased after N but not after V (see Table).
Psyst
mm Hg
Pdiast
mm Hg
Reactivity
toNA toPH
xg/kg/min
Control 144 4 99 2 11 2 0.9 0.1
Nifedipine 129 3* 87 3* 5 r 0.5 o.r
Control 149 5 97 3 8 I —
Verapamil 132 4* 86 4 7 I —
a2-sites
fmole/mg/prot
AC
%
Control 206 9 100
Nifedipine 169 7* 79 5a
Control 172 10 100
Verapamil 192 12 91 8
5P < 0.01.
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Since reduction of NA reactivity was associated with a decrease in
a2-receptors, the reduction of PH reactivity suggests a decrease of
a1-receptors as well. The antihypertensive effect of N but not of V may
be due in part to a reduced density and function of a1- and a2-receptors.
Hemodynamic, renal, and endocrine effects of urapidil in hypertensives
with normal and impaired renal function. G. Wambach, W. Heitz, and
K. A. Meurer. Department of Medicine II, University of Cologne, Köln,
Federal Republic of Germany. The pharmacological profile of urapidil,
a new hypotensive substance with central and peripharal a1-blocking
properties is not completely characterized. We, therefore, studied
changes in systolic, diastolic, and mean arterial pressure (MAP), heart
rate (HR), renal blood flow (RBF), glomerular filtration rate (GFR), as
well as plasma-renin activity (PRA) and serum aldosterone (SA) after
i.v. injection of urapidil (25 mg) in ten patients with essential hyperten-
sion (EH) (nine male, one female, aged 48 7 years), in ten patients
with hypertension and chronic renal failure (CRF) (three male, seven
female, aged 46 19 years), and in ten normotensive controls (three
male, seven female, aged 25 2 years). Ten mm after injection of
urapidil, MAP declined from 85 6 to 74 7 mm Hg in the controls;
HR rose from 68 to 74 (min). In patients with EH, MAP significantly
dropped, from 126 to a minimum of 108 mm Hg, and in patients with
CRF, MAP was lowered from 127 to 109. Maximal hypotensive reaction
was seen between 10 and IS mm after urapidil in all three groups. RBF
and GFR remained constant in all subjects over a period of 135 mm.
PRA and SA increased by 15 to 70% after injection of urapidil in all
three groups. In conclusion, urapidil acutely lowers systemic arterial
blood pressure in hypertensives, both with normal and impaired renal
function, paralleled by an activation of renin-angiotensin-aldosterone
system. Despite a significant drop in blood presure, renal function
remains unaltered.
Studies on pharmacokinetic drug interactions with verapamil. J.
Mooy, B. Arends, R. Böhm, J. v. Kemenade, and K. H. Rahn.
Departments of Medicine and Pharmacology, University of Limburg,
Maastricht, The Netherlands. The calcium entry blocker, verapamil, is
now used frequently for the chronic treatment of hypertension and
given concomitantly with other drugs. Verapamil is extensively metab-
olized by the liver. Hepatic enzymes can be inhibited by cimetidine and
induced by rifampicin. Therefore, the influence of these drugs on the
pharmacokinetics of verapamil was studied. Plasma levels of the
calcium entry blocker were determined by means of high-performance
liquid chromatography with fluorometric detection. Six subjects re-
ceived a single oral dose of 40 mg verapamil. Subsequently, the plasma
levels of the drug were determined repeatedly for a total of 7 hrs. The
study was repeated after the subjects had been treated for 5 days with
oral doses of cimetidine (400 to 1000 mg/day). Furthermore, 40 mg
verapamil was given orally to four patients with tuberculosis. These
patients had been treated for at least 6 months with a combination of
rifampicin (450 to 600 mg/day), isoniazide (5 mg/kg/day), and
ethambutol (15 mg/kg/day). After a single oral dose of 40 mg verapamil,
a maximum plasma concentration (cmax) of the drug of 39.5 7.6ng/ml
was reached after 85 9 mm in subjects not pretreated with other
drugs. Terminal slope half-life was 191 29.3 mm, with an area under
the curve (AUC) of 9939 1593 ng ml mm. Pretreatment with
cimetidine did not alter these parameters (P > 0.1). In contrast,
tuberculostatics had a pronounced effect on the plasma levels of
verapamil. The cm,,, of the calcium entry blocker was 20.3 ng/ml in one
patient treated with tuberculostatics, and less than 5 ng/ml in the other
three. This resulted in an AUC of less than 3700 ng ml mm. The
study demonstrates that cimetidine has no influence on the
pharmacokinetics of verapamil. Treatment with tuberculostatics, how-
ever, strongly reduces the bioavailability of the calcium antagonist.
This effect is most probably due to enzyme induction by rifampicin.
One must assume that tuberculostatic treatment, as used in this study,
significantly reduces the efficacy of oral verapamil.
Acute effects of enalapril and furosemide, alone and in combination, on
blood pressure, renal hemodynamics, and tubular sodium resorption. W.
J. de Goede, G. G. Geyskes, P. Boer, J. C. Roos, and E. J. Dorhoug
Mees. Department of Nephrology, University Hospital, Utrecht, The
Netherlands, Blood pressure (BP) and renal function during maximal
free water clearance have been studied in seven patients with essential
hypertension on one day during placebo and on another day during
maximal converting enzyme inhibition (CEI), achieved by an oral dose
of 20 mg enalapril. During both study periods, the effect of furosemide
(.2 mg/kg i.v.) was assessed. CEI induced a decrease of the BP from 3
to 32%. Mean glomerular filtration rate (GFR, by C-inuline), remained
unchanged, but GFR increased in patients with low PRA and decreased
in patients with a high PRA and a more substantial drop of mean arterial
pressure (MAP). Effective renal plasma flow (C-PAH) increased in all
patients (from II to 56%); filtration fraction decreased. No changes
were observed in average absolute or fractional CNa, CK, and
CH2O, but fractional CCI- and Cosm decreased. Proximal tubular Na
reabsorption was calculated from CH2O and from Clithium: with both
methods no change was found. Distal Na reabsorption was slightly
(1.8%), but significantly, higher during CEI. Changes of these tubular
functions did not correlate with the decrease of the BP. Furosemide (.2
mg/kg i.v.) did not change BP, but increased absolute and fractional
CCI, CNa, CK, and Cosm; distal, but also proximal Na reabsorp-
tion was suppressed. These changes were similar during placebo and
CEI, in accordance with unchanged intrarenal Na handling during
CEL. It is concluded that CEI with enalapril increases renal plasma flow
and disrupts the autoregulation of the GFR. The absence of a natriuretic
effect and of major changes in intrarenal sodium handling is probably
due to opposite effects of the decrease of angiotensin II and BP, which
apparently act on the same sites of the renal tubule. This concept is
supported by the observation that effects of furosemide are not influ-
enced by acute CEI.
Use of captopril in the diagnostic work-up of renovascular hyperten-
sion. F. H. M. Derkx, H. L. Tan-Ti iong, G. J. Wenting, A. J. Man in 't
Veld, and M. A. D. H. Schalekamp. Department of Internal Medicine
I, Erasmus University, Rotterdam, The Netherlands. The use of
captopril (C) for the diagnostic work-up of renovascular hypertension
was assessed in 183 consecutive hypertensive patients; 62 had unilateral
renal artery stenosis (URAS) on angiography, 41 had bilateral abnor-
malities (BIRAS), and the remainder had essential hypertension (EHT).
All patients were off treatment for at least 2 weeks and measurements
were made while patients had a 50 mmoles/day sodium intake. Periph-
eral vein renin before C was elevated in 56% of URAS, in 58% of
BIRAS, and in 10% of EHT patients. The discriminative power of
peripheral renin measurements was greatly improved after 50 mg of C.
After I hr, peripheral vein renin was above 200 MU/mI in 36 out of 39
URAS, in 16 out of 20 BIRAS, and in only three out of4l EHT patients.
The effects of C on blood pressure in URAS, BIRAS, and EHT,
however, were not significantly different. A renal vein-to-artery ratio
for renin (V/A) of at least 1.50 was found in 43 out of 46 URAS patients
on the stenotic side and in two contralaterally, in 31 out of 41 BIRAS
patients on the most seriously affected side and in six contralaterally,
and in six out of 47 EHT patients on one side and in two on both sides.
V/A in URAS, BIRAS, and EHT was not significantly altered by C,
despite a marked increase in renin secretion. The blood pressure-
lowering effect of 4 weeks of treatment with C (150 mg t.i.d.) in 24
URAS was weakly correlated with the effect of surgery as measured
after three months (r = 0.44, P <0.05 for systolic pressure and r = 0.53,P < 0.01 for diastolic pressure). We conclude that measurement of
peripheral vein renin after stimulation by C may be useful for selecting
hypertensive patients for renal angiography. Increased V/A before and
after C is a measure of decreased renal blood flow rather than increased
renin production. Blood pressure response to C has limited value for
predicting surgical outcome,
Impaired fibrinolytic potential and missing protein C Increase in severe
kidney graft rejection. R. Seitz, H. Lange, and R. Egbring. Zentrum für
Innere Medizin, Philipps-Universitat, Marburg, Federal Republic of
Germany. After kidney transplantation, coagulation and fibrinolysis
were assessed in 20 patients. The 13 patients who experienced severe
rejection (ten grafts had to be removed) exhibited an impaired
fibrinolytic potential, caused by a decrease of plasminogen and an
increase of a2-antiplasmin. This means a preponderance of the inhibi-
tor, expressed by a high a2-antiplasmin/plasminogen ratio. The reduc-
tion of the fibrinotytic capacity was demonstrated by a "reversed fibrin
plate" assay. Since the neoantigen a2-antiplasmin-plasmin complex
was not detected in any patient's plasma, systemic hyperfibrinolysis is
not likely to account for the low plasmmnogen. The protein C levels were
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slightly elevated before transplantation. They rose significantly only in
the patients without serious rejection. Since a common autoptic finding
in grafts removed due to rejection are intravascular thrombi, an
impaired fibrinolytic capability and a missing incresae of the antithrom-
botic protein C may have significance for graft survival.
Cyclosporin A (Cy A) therapy with or without steroids in cadaveric
kidney transplantation. A prospective randomized one-center study. F.
W. Albert and U. Schmidt. Medizinische Klinik III, Städtisches
Krankenhaus, Kaiserslautern, Federal Republic of Germany. In a
prospective randomized study in 1983 and 1984, we compared a group
(A) of 23 kidney transplant patients who were primarily treated with Cy
A with a group (B) of 23 transplant recipients under a combined Cy
A/steroid therapy. The patients were distributed almost homogenously
over the two groups with regard to sex, age, underlying disease, number
of prior transfusions, HLA mismatches, cytotoxic antibodies, and total
ischemia time. Cy A was administered perorally in an initial dosage of
15 mg/kg body wt (or 5 mg/kg intravenous) under subsequent adaptation
of the dose divided into two portions to the Cy A trough level in the
whole blood (range aimed for between 250 and 700 ng/ml). The steroids
were given in a daily dosage of 0.5 mg fluorcortolone/kg body wt. After
3 to (at the latest) 6 months, the steroids were completely discontinued
in all cases. In the first group, rejection reactions were treated on
principle without steroids, and only with antithymocyte globulin. In the
second group, methylprednisolone was administered in rejection crises
in high dosage. In therapy-resistant rejection and in medication intol-
erance, the treatment schedule was changed. This had to be carried
from A to B in eight cases, and only once (because of steroid ulcer) from
B to A. In the two groups, four patients were switched to a conventional
treatment technique with azathioprine. Eleven patients did not receive
steroids at any time. The one-year patient survival rate was 96% in both
groups. The one-year transplant function rates, likewise, did not show
any significant differences (77% in group A as compared to 82% in group
B). We consider that it is possible to dispense with steroids from the
beginning in a substantial proportion of transplanted patients with initial
treatment by Cy A alone. Despite the delayed additional therapy with
steroids necessary only as expressly required, the prognosis of the
transplants did not deteriorate.
Differential expression of HLA-DRI-DP/-DQ antigens on human renal
tissue. G. A. Muller, T. Risler, J. J. Weening, H. Bockhorn, U, Hopt, G.
H. Muller, L. Hofmann, and C. Muller. Department of Pathology,
University of Leiden, Leiden, The Netherlands, and Medical University
Clinics, Department of Surgery, University of Tubingen, Tubingen,
Federal Republic of Germany. In clinical kidney transplantation, mol-
ecules of the MHC, especially antigens of the HLA-D region, play a
major role for graft prognosis. Therefore, the precise localization of
these MHC-coded products on renal parenchymal cells is of great
interest. Cryostat sections of ten normal and 20 pathological human
kidneys presenting with glomerulonephritis were investigated for the
expression of HLA-D region products by immunoperoxidase staining
using a subset of three monoclonal antibodies, detecting different
monomorphic HLA-D region molecules. TU22 was previously reported
to recognize HLA-DQ, TU34 detects HLA-DR, whereas FA (a gener-
ous gift from F. Bach, Minneapolis, Minnesota, USA) determines
HLA-DP products. In normal renal tissue, TU34 was found to react
with all endothelial cells of capillaries, big veins, and arteries, as well as
of the glomerulus and with "dentntic" cells of the interstitium. The
mesangial cells seemed to be HLA-DR positive by light microscopy.
Variable staining of TU34 was found in epithelial cells, particularly of
the proximal tubuli. In contrast labeling of HLA-DQ, determinants by
TU22 was confined to "dentritic" cells of the interstitium, whereas the
reactivity on glomerular endothelial cells was rather weak. Tubular
epithelial cells never stained positive with TU22. In addition, HLA-DP
molecules were not expressed on tubular epithelial cells, but were
detected on all glomerular endothelial cells and on some interstitial
cells. In biopsy specimens of diseased kidneys, increased staining of
TU34 on all tubular epithelial cells, except those of the collecting duct,
was found, whereas TU22 remained negative on all tubular cells. This
selective expression of different HLA-class LI products on renal paren-
chymal cells suggests differential contributions of distinct renal cells in
organ-specific immune response.
Value of needle biopsy in renal transplantation. G. H. Muller, B.
Greger, W. Schareck, U. T. Hopt, G. Muller, H. Bockhorn, and T.
Risler. Chirurgische Universitatsklinik Tubingen, Tubingen, Federal
Republic of Germany. Needle biopsies (NB) have been shown to be
useful in the management of renal allograft recipients. NB were done in
our center to differentiate rejection from other causes of impaired renal
function (cyclosporin nephrotoxicity, ATN, recurrence of original
disease) and to control our immunosuppressive regimen before, during,
and after rejection therapy. To evaluate risk and benefit of NB, 200
consecutive NB (Trucut, Travenol) were studied. The clinical diagnosis
before NB was compared with the histology, and the prognostic value
of a histological grading in the degree of cellular and vascular rejection
was studied. Common complication after NB was bleeding extra- and
intrarenal, often seen only by ultrasound scanning, and, in most
patients, seen as hematuria. Due to this complication, three patients in
this consecutive series of 200 NB lost their graft. However, NB, leading
to the diagnosis of ATN or drug-induced renal failure or other non-
immunological malfunction, resulted in a lowering of the immunosup-
pressive treatment or avoidance of additional rejection therapy. Control
of renal function after rejection therapy in the case of cellular rejection
showed an excellent susceptibility to treatment, which was not seen in
combined cellular/vascular or vascular rejection episodes. The fre-
quency of ATN and non-immunological malfunction such as cyclospo-
rin-induced nephrotoxicity in NB leads to a significant lowering of
immunosuppressive therapy and may result in a decrease in infection
rate and an increase in patient survival.
Damage to transplanted kidneys indicated by urine protein patterns
under cyclosporine A and conservative treatment. M. Domann, H.
Loew, R. Windeck, H. D. Jakubowsky, and F. W. Eigler. Department
of Nephrology, Alfried Krupp Hospital, and Department of Surgery,
University Hospital, Essen, Federal Republic of Germany. A retrospec-
tive study of the influence of cyclosporine A on posttransplant renal
damage is presented. Twenty-one patients under cyclosporine A (CA)
and 15 under conservative (CO) treatment (azathioprine) were studied
by polyacrylamidgel electrophoresis of the urine, whole blood CA and
serum creatinine levels. Mean creatinine was 1.77 mg/dl in group CA
and 1.69 in group CO. 3 to 6 months posttransplant. 40% of CA patients
but only 15% of CO patients had normal urine patterns 3 to 6 months
posttransplantation. 15% of CA patients but 20% of the CO patients had
low molecular weight proteinuna (type 1) only, and 45% of the CA
patients but 65% of the CO patients had low and high molecular weight
(mixed) proteinuria (type II). Isolated high molecular weight proteinuria
was not observed. Seven of 12 patients with CA blood levels below 400
ng/ml had normal urines, three type I and two type II patterns, whereas
only one of nine patients with CA levels above 400 nglml had normal,
three type I and five Type II patterns. The mean creatinine levels were
1.6 in the 12 patients with CA levels below 400 ng/ml and 2.0 in eight
patients with CA levels above 400 ng/ml, 3 to 6 months posttransplanta-
tion. Cold ischemia time was equal in the CA and CO group, averaging
28 hrs. Conclusions: 1. At 3 to 6 months post transplantation, there was
no significant difference between the serum creatinine levels of the CA
and the CO group. 2. Under CA, significantly more transplanted
kidneys produce normal urine than under CO treatment. 3. Low CA
levels (below 400 ngldl) do not seem to affect adversely the transplanted
kidney during the first 3 to 6 months in contrast to high levels of CA
(above 400 ng/ml).
Evidence of herpes simplex virus in urine with different infection
symptomatology after kidney transplantation. E. Schulz, R. H. Dennin,
J. Steinhoff, R. Daihoff, and K. Sack. Klinik fur Innere Medizin,
Institut für Medizinische Mikrobiologie, Medizinische Hochschule
Lübeck, Lübeck, Federal Republic of Germany. The virus excretion in
urine is mostly a sign of viremia. In exceptionally severe cases of
Herpes simplex virus (HSV) serotype 1 infections in immunosup-
pressed patients, very rarely viremia, have been described. The
posttransplantation protocols of four patients under immunosuppres-
sive therapy with cyclosporinlprednisolone are discussed. Preopera-
tively, four of four patients were serologically HSV-positive (enzyme
immunoassay); posttransplantation, the HSV- and CM V-specific 1gM-
and IgG-antibody titers were determined in regular intervals, further
attempts of virus isolation in cell cultures out of urine and throat-rinsing
liquid were made. In the urine of four of four patients and additionally
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in the throat-rinsing liquid of one of four patients, HSV serotype 1 was
demonstrated; in none of the patients, HSV typical symptoms, such as
Herpes labialis or stomatitis, were noticed. Two of four patients
showed both clinically and serologically (CMV-lgM positive) a CMV
infection. The third patient presented mild, probably infection-asso-
ciated symptoms, with short-termed arthralgia. With the fourth patient,
merely a vague infection symptomatology with recidivating sinusitis of
unclear etiology could be observed. The results indicate that with
immunosuppressed kidney transplanted patients, HSV reactivations
can be expected occasionally and cause an infection symptomatology
difficult to classify, or which can complicate other simultaneously
proceeding infections, such as CMV. Serological data alone often
disclose insufficient information.
Incidence and progress of CMV infections after kidney transplantation
under cyclosporinlprednisolone therapy. E. Schulz, R. H. Dennin, K.
Sack, K. Daihoff, and J. Hoyer. Klinik fur Innere Medizin, Institut fur
Medizinische Mikrobiologie, Klinik für Chirurgie, Med. Hochschule,
Lübeck, Federal Republic of Germany. In 45 kidney-transplanted
patients, immunosuppressed with cyclosporinlprednisolone, incidence
and clinical progress of CMV infections were studied. Under strict
clinical supervision, the CMV-specific 1gM- and IgG-antibody titers
(enzyme immunoassay) were checked in intervals of 2 weeks, at least,
during the first 6 months after kidney transplantation. For prophylaxis,
11 CMV-seronegative patients were given CMV-hyperimmunserum.
Regarding the titer courses, with 28/45 patients (62%), the diagnosis of
a serologically active CMV infection was made. In eight cases, the
infection proceeded clinically inapparent. Twenty of the patients be-
came ill with clinical manifestations, 14 showed a mild or moderate and
six a severe clinical course (two lost their transplants). In five of the 11
seronegative, passively immunized patients (45%), signs of a serologi-
cally active CMV infection were found, only three of eleven showed
clinici manifestation, of these, two clinical courses were severe; the
other showed a mild progress. Under cyclosporin/prednisolone ther-
apy, the incidence of CMV infections after kidney transplantation
appear to be as frequent, the percentage of clinically active diseases to
be of the same range, and the clinical courses mostly milder than under
the former, usual immunosuppression with azathioprin. By passive
immunization of CMV-seronegative patients, CMV infections cannot
be prevented.
Ocular side effects of immunosuppression after renal transplantation:
Cyclosporin A versus conventional therapy. H. Kopsa, H. Bettelheim, E.
Winkler, R. Schmidt, J. Zazgornik, and P. Balcke. First Medical Clinic,
Second Ophthalmologic Clinic, University of Vienna, Vienna, Austria.
Seventy-two renal transplant patients were screened for ocular findings
after successful grafting. Forty-one cases (group I) received
prednisolone and azathioprine, the observation time ranged from Ito 40
months (mean observation time, 8.7 months). In 31 recipients (group
II), low-dose steroid therapy and cyclosporin A were administered for
2 to 25 months (mean observation time, 11.1 months) after surgery.
Ocular check-up comprised clinical examination of the eye, slit-lamp,
tonometry, visual acuity, and fundoscopy. Results: Recurrent
subconjunctival hemorrhages and calcium deposits in the conjunctival
tissue occurred in 61% of group I and 40% of group II. The incidence of
posterior subcapsular cataract (PSC) was 61% in the patients under
conventional immunosuppression and 21% under cyclosponn A. Visual
acuity in cases with PSC was not impaired, except in one case in group
I. Dose reduction of corticosteroids was followed by diminution of
PSC. Elevated intraocular pressure and steroid glaucoma, respectively,
were measured in two cases in group I. Fundoscopic findings in groups
I/Il were pigmentary irregularities of the fundus (44/42%), alterations of
the foveolar region (12/17%), and of papilla N. optici (3/0%). Conclu-
sion: Undercyclosporin A administration with low-dose prednisolone,
subconjunctival hemorrhages and PSC occurred less frequently than
under conventional immunosuppression. Fundoscopic findings did not
differ in both groups; hypertensive retinopathy, however, was more
frequent in group II.
Requirements for the virus-specific relevant evaluation of antibody
titers in kidney transplant patients under immunosuppressive therapy
with cyclosporin. R. H. Dennin, E, Schulz, K. Dahlhoff, and K. Sack.
Institut für Med. Mikrobiologie and Klinik für Innere Medizin,
Medizinische Hochschule Lübeck, Lübeck, Federal Republic of Ger-
many. Conventionally, the serodiagnosis of virus infections is based on
the measurement of virus-specific antibody titers, namely, the absolute
IgG-titer value, and, more valuable, the variation in the antibody titers
in the course of time, besides the virus-specific 1gM-titers. With an
enzyme-linked immuno sorbent assay (ELISA), it became possible to
determine virus-specific antibody titers precisely with high sensitivity.
Our long-time study with kidney transplant patients, that is, parallel
measurements of cytomegalovirus (CMV), herpes simplex virus (HSV),
rubella, and Epstein-Barr virus antibody titers in serum and the
serum-IgG-concentrations, revealed that the above-mentioned criteria
for serodiagnosis are not allowed to be applied generally to the situation
of patients with immunosuppressive therapy without further consider-
ations. Our observations demonstrate that just in patients under
cyclosponne therapy, virus-specific antibody titers (for example, CMV)
can behave abnormally. Sometimes, increases in titers can occur not
only as a response to an active virus-induced infectious process, but
also emerge as the result of an increase in the total serum-IgG
concentration. In the latter cases, the other virus-specific antibody
titers increase, too. Therefore, to discriminate between antibody titer
increase due to an active virus infection and nonspecific increase, it
seems necessary to measure at least two other virus-specific antibody
titers, one of a so-called latent virus, for example, herpes simplex, and
a non-latent virus, such as rubella.
Cyclosporin A serum levels: Reciprocal correlation between required
dosage and the corpulence index (CI). B. Greger, W. D. Schareck, G. H.
Muller, U. T. Hopt, and H. Bockhorn. Chirurgische Univeritätsklinik
Tubingen, Tubingen, Federal Republic of Germany. Clinical evidence
indicated that smaller kidney-transplanted patients require a higher
dosage of CsA per kg body wt (BW) than more corpulent ones to
maintain their serum levels. This seems to be surprising, since CsA
molecules show lipophilic properties. One would expect a higher drug
depot and, therefore, a required dosage in corpulent persons. To study
this contradictory phenomenon, we calculated in 65 patients with
kidney allografts: a) the amount of CsA per kg body wt, which each
patient required to maintain a therapeutical serum-CsA level; b) the
body wt (kg)
corpulence-index (CI), expressed by ; and c) the
height (cm) — 100
CsA-dosage effectiveness in each patient, as expressed by the serum
level/dosage quotient. There is a clear-cut reciprocal correlation be-
tween the corpulence-index and the required CsA dosage; similarly, the
dosage effectiveness is higher in larger and lower in smaller patients.
These data suggest that in addition to other parameters, such as uptake
and drug metabolism, the corpulence index seems to be decisive for the
respective serum level of CsA. Thus, the inverse correlation between
the corpulence index and the maintenance dose of CsA found may
facilitate the dose adjustment of cyclosponn A in the early posttranspl-
ant period and contribute to our understanding of the toxic immunosup-
pressive effects of CsA.
Disorders of the cerebral nervous system (CNS). Their significance in
the early posttransplant period. W. D. Schareck, B. Greger, U. T. Hopt,
G. H. Muller, H. Bockhorn, and I. Risler. Chirurgische und
Medizinische Universitätsklinik Tubingen, Tubingen, Federal Republic
of Germany. Severe disorders of CNS are relatively rare in patients
with chronic renal failure. After renal transplantation, however, a
considerable portion of these patients, who did not show any neurolog-
ical symptoms previously, develop severe neurological symptoms.
Since the clinical picture of these neurological disorders, as well as their
prognosis, is quite different in these highly immunosuppressed patients,
we revisited all of our patients with severe cerebral symptoms in the
early posttransplant period. 246 patients were included in the study;
thirteen of these developed severe cerebral disorders in the first few
weeks after transplantation and nine patients suffered from repeated
grand mal seizures. In addition, in three patients, a transient delirious
state was seen, which could not be related to the operation and
anesthesia. In eight of these patients, symptoms resolved spontane-
ously or after restoration of electrolyte balance and reduction of the
cyclosporin A dosage. In contrast, in the other patients, the symptoms
were signs of septic complications, cerebral abscesses, or hemorrhage.
Although neurological symptoms could clearly be demonstrated clini-
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cally, diagnosis was delayed in all patients because of negative roent-
genological and laboratory findings. Examination of the liquor, EEG,
and repeated CT scans of the brain provided significant pathological
results only 1 to 2 weeks after the onset of the neurological symptoms.
This was true for bacterial, viral, and fungal encephalitis. Mortality in
the patients was very high. Three of the four patients died, in spite of
complete cessation of the immunosuppressive therapy. Although neu-
rological symptoms in transplanted patients may resolve spontane-
ously, their occurrence should be alarming and initiate an intensive and
complete work-up of the patient. Exclusion of any kind of septic state
is mandatory, and must be pursued as intensively as possible. If the
neurological disorders cannot be explalned by a toxic cyclosporin A
level or general disorders of the homeostasis, immunosuppression
should be drastically reduced or stopped completely. Specific antibac-
terial or antifungal therapy should be started according to the clinical
diagnosis. Waiting for pathognomonic, roentgenological, and labora-
tory findings will delay specific therapy, and may be, in part, respon-
sible for the alarming mortality rate in this group of patients.
Prednisolone and the development of hypertension after allogeneic
kidney transplantation in the rat. M. H. De KeUzer, A. P. Provoost, E.
D. Wolff, and J. C. Molenaar. Departments of Pediatric Surgery and
Pediatrics, Erasmus University, Rotterdam, The Netherlands. An
experimental model to study the development of hypertension after
kidney transplantation (KTX) was developed. In this model, we used
allogeneic KTX between two inbred rat strains. Graft survival was
prolonged by pretreatment of the recipient with donor strain blood
(DSB). A rise in systolic blood pressure (SBP) was observed during the
second week after KTX. The hypertension was most probably due to an
incomplete prevention of rejection. The effect of additional immunosup-
pression on the development and persistence of the post-KTX hyper-
tension was investigated in the rat model by administering prednisolone
(Pr) alone or adjuvantly with DSB pretreatment. Administration of Pr in
doses of 2, 4, or 8 mg/kg/day for the first 2 weeks after KTX (by
continuous infusion using osmotic minipumps) to DSB-pretreated re-
cipients resulted in an increase in the SI3P during Pr administration.
However, the recipients became normotensive once the Pr infusion was
stopped. The effects of the same doses of Pr upon the SBP in
unilaterally nephrectomized control rats were similar to those obtained
in kidney allograft recipients, indicating that the hypertension observed
during Pr administration was due to the hypertensiogenic effect of this
steroid. Rats treated with Pr in a dose of I mg/kg/day, adjuvant to DSB,
remained normotensive throughout the observation period. Lowering
the dose of Pr to 0.5 mg/kg/day masked its immunosuppressive prop-
erties. These recipients showed a similar rise in SBP after KTX as those
treated with DSB only, while the hypertension persisted after cessation
of the Pr administration. The use of Pr without DSB pretreatment was
found to be less immunosuppressive than the combined treatment.
Continuous infusion of Pr in a dose of 2, 4, or 8 mg/kg/day for 2 weeks
did prolong the graft survival after KTX, but these recipients showed a
rise in SBP, and remained hypertensive after cessation of the Pr
infusion. We conclude that in our rat model of hypertension after KTX,
with DSB pretreatment to prolong graft survival, the high SBP results
from incomplete prevention of rejection. When Pr is used for im-
munosuppression, a steroid-induced hypertension may develop. When
used alone, the dose of Pr to prolong graft survival causes hypertension.
When Pr is administered as adjuvant immunosuppressive treatment, the
rise in SBP might be prevented by careful adjustment of the Pr dose.
Too low a dose carries the risk of losing the additional immunosuppres-
sive effect, resulting in a rejection-induced hypertension.
Donor erythrocyte-mediated prolonged renal allograft is an organ-
specific phenomenon. P. J. C. van Breda Vriesman, L. M. F. Viek, C. C.
M. Heuts, and G. D. Majoor. Department of Immunology, State
University of Limburg, Maastricht, The Netherlands. Whether or not
class LI MHC antigens are required for the beneficial effect of donor
blood transfusion on renal allograft survival is a topic of debate. This
question was examined in a rat model using donor erythrocytes, which
lack class II but possess class I MHC alloantigens, to induce unrespon-
siveness to these antigens in allogeneic recipients. Pretreatment of BN
or LEW rats with large doses of highly purified LEW and BN
erythrocytes, respectively, induced specific unresponsiveness to class I
antigens and was associated with a markedly prolonged survival of
renal aiiografts from LEW (MRT > 40 days) and BN (MRT 15 days),
respectively, Cardiac and skin allografts were rejected acutely by both
BN and LEW. The prolonged survival of renal allografts was not due to
uremia; both cardiac and renal allografts failed to break tolerance to
class I antigens. To rule out that the organ specificity observed above
was due to non-MHC antigens, BN rats were made unresponsive to
LEW, and, next, organs from BN.IL rats (LEW MHC on the BN
genetic background) were transplanted; BN. IL hearts were acutely
rejected (MRT 7 days), whereas BN. 1L kidneys showed a prolonged
survival (> MRT > 40). Using a paired-labeled binding assay, class II
alloantigens were not demonstrable on the endotheiial cells of heart or
kidney. These results suggest that the kidney differs from the heart in
passenger leucocyte-mediated alloimmunogenicity or, alternatively,
that the kidney, compared to the heart, is less likely to be irreversibly
damaged by an immunological assault directed against the vasculature.
Complement activation associated with active cytomegalovirus infection
in renal transplant patients and its absence in transplant rejection
episodes. W. J. van Son, F. J. van der Woude, G. K. van der Hem, T.
H. The, Th. Ockhuizen, and A. M. Tegzess. University Hospital
Groningen, Groningen, The Netherlands. The incidence of active
cytomegalovirus (CMV) infection has been stated as high as 43 to 92%
after cadaveric renal transplantation. To differentiate between an active
CMV infection and acute allograft rejection (R) can be very difficult
because fever, a rise in serum creatinine, a swollen, painful kidney, as
well as abnormalities in graft biopsy specimens may also be found
during a CMV infection. Measurements of the serum complement (C)
system during R have no diagnostic significance. We studied 20 renal
transplant patients in a prospective way by serial quantitative measure-
ments of C4, factor B (FB), C3, and the C-activation product, C3d. The
aim of the study was to investigate whether C is activated during an
active CMV infection and if this can be of any help to differentiate
between R and CMV infection. Fifteen patients had one or more R
episodes, while nine patients suffered from an active CMV infection.
Six patients had an R episode and, subsequently, a CMV infection 13 to
64 days after R. Two patients had neither R nor CMV infection. No
significant changes were found in the levels of C3, C4, and FB during R
or CMV infection. C3d levels remained unchanged or decreased slightly
during R. However, there was a 43 to 500% increase in C3d level during
CMV infection. This difference in behavior of levels of C3d during R
and CMV infection is statistically significant (P < 0.01), and suggests
that C is activated during an active CMV infection after renal trans-
plantation. We conclude that serial measurements of C3d are of help to
differentiate between R and CMV infection after renal transplantation.
Expression of class I MIIC antigens on the vascular endothelium of
mouse skin allografts. R. M. W. de Waal, M. J. J. T. Bogrnan, and R.
A. P. Koene. Departments of Pathology and Medicine, Division of
Nephrology, Si. Radboud Hospital, University of Nijmegen, Nzjmegen,
The Netherlands. The aim of this study was to investigate the expres-
sion of donor class I MHC antigens on the vascular endothelium of an
aiiograft in vivo. The experiments were performed in a mouse skin
allograft model. Recipients of skin allografts were injected i.v. with
radiolabeled or biotinylated monoclonal antibodies directed against a
class I MHC antigenic allodeterminant, and, after a certain time
interval, the grafts were removed and the amount and the localization of
bound antibodies were determined. Immunofluorescence microscopy
showed that the binding was localized exclusively on cells of the
capillary endothelium. This in vivo binding model was then used to
study the expression levels of endothelial class I antigens in skin
allografts. Our findings showed that: 1. The binding of the anti-class I
monoclonal antibody to endothelial cells shows the same specificity as
was found in lymphocytotoxicity analysis. 2. The amount of binding is
subject to strain variations. 3. The binding in long-standing skin
allografts is variable in the course of time. 4. The levels of binding are
governed by the immune status of the recipient: suppression (through
administration of cyclosporin A) or absence (using nu/nu recipients) of
T-cell-dependent immunity results in low or undetectable levels of
anti-class I antibody binding in the graft. 5. Induction of an immune
response against the allograft induces class I antibody binding in the
graft, or increases an already existent binding capacity. From these
findings, we conclude that the expression of class I MHC antigens on
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the vascular endothelium of mouse skin allografts is variable, and is
induced and maintained by activation of T-cell-dependent immunity.
Lymphocytotoxins associated with acute CMV infections in renal
transplant recipients. W. M. Baldwin II!, F. H. J. Claas, G. W. van
Gemert, L. C. Paul, F. C. Henny, M. R. Daha, and L. A. van Es.
Nephrology, Immunohematology, and Virology Departments, Univer-
sity Hospital, Leiden, The Netherlands. We have reported that
lymphocytotoxins are produced by renal transplant recipients during
active CMV infections. We are now better defining these antibodies.
Since January, 1980, sera from all adult renal graft recipients at our
center who had serological or culture evidence of CMV infections were
tested for lymphocytotoxins. Polyethyleneglycol (PEG) precipitates
and supernatants were tested on panels of peripheral blood cells in the
standard NIH test at 20C. Sera from 48 of 59 patients with CMV
contained lymphocytotoxins during the infection. Treatment with 3.5%
PEG precipitated the lymphocytotoxins totally in 20 sera, partially in II
sera, and not at all in 17 sera. In contrast, sera from eight of 15 control
patients undergoing acute graft rejection without active CMV infection,
and 15 of 15 hyperimmune patients contained primarily lymphocytotox-
ins that were not precipitated by PEG. PEG-precipitable lymphocyto-
toxins were shown to be 1gM antibodies by ultracentrifuge and im-
munofluorescent studies, whereas PEG nonprecipitable antibodies
were IgG. When HLA-A, B, and DR were either blocked or "stripped
off" by pretreatment with monoclonal antibodies, the target lympho-
cytes were still lysed by the PEG-precipitable antibodies, but not by the
nonprecipitated antibodies. PEG-precipitable antibodies lysed 50 to
100% of a panel of unseparated lymphocytes, as well as isolated B-cells,
T-cells, monocytes, and granulocytes, but not platelets. Irreversible
graft rejection occurred in ten of 20 CM V-infected patients with only
PEG-precipitable lymphocytotoxins and eight of 17 patients with only
nonprecipitable antibodies, but in only one of 11 patients with no
lymphocytotoxic antibodies. Thus, CMV disease in renal graft recipi-
ents is associated with PEG-precipitable, non-HLA directed, 1gM
antibodies that can lyse B-cells, T-cells, monocytes, and granulocytes,
but not platelets. These antibodies may be deleterious to graft survival.
Inhibition by cyclosporin A (CyA) of antigen. and mitogen-induced
lymphocyte proliferation is not primarily due to diminished interleukin.2
(11-2) production or 11-2 receptor expression. M. H. J. van Oers, S. L.
Yong, P. Th. A. Schellekens, andJ. M. Wilmink. Central Laboratory of
the Netherlands Red Cross Blood Transfusion Service and Laboratory
for Experimental and Clinical Immunology, University of Amsterdam,
Amsterdam, The Netherlands. The mode of action of the immunosup-
pressive agent, CyA, is still unknown. In studies on the influence of
CyA on the 11-2 system, conflicting results have been obtained. We
investigated the effect of CyA on (allo-) antigen- and mitogen-induced
proliferation of human peripheral blood lymphocytes. Our results can
be summarized as follows: 1) CyA causes a reversible dose-dependent
inhibition of (allo-) antigen- and mitogen-induced proliferation; prolif-
eration induced by the tumor promoter, PMA, is CyA resistant. 2) The
11-2 production by stimulated lymphocytes is only moderately de-
creased by CyA; addition of exogenous 11-2 does not restore the
proliferative response. 3) CyA does not inhibit the interaction between
11-2 and its receptor. 4) Expression of 11-2 receptors, as measured by the
presence of the Tac antigen as well as by the capacity to absorb 11-2, is
not significantly inhibited by CyA. Combination of our results with
recent literature on cellular activation by PMA (via protein kinase C)
results in a hypothesis on the mode of action of CyA.
The value of the ifitration fraction (FF) and the relative Tc-DMSA
clearance (DMSA ratio) in cadaveric renal allograft recipients (CR) under
cyclosporine A (CyA) or conventional treatment. A. M. Tegzess, S.
Meyer, W. J. van Son, F. J. van der Woude, M. J. H. Slooff, W. J.
Sluiter, A. J. M. Donker, and D. A. Piers. State University Hospital,
Groningen and Free University Hospital, Amsterdam, The Nether-
lands. In earlier studies, we have shown that a high DMSA ratio
indicates proximal tubular dysfunction. Differentiation of rejection from
CyA nephrotoxicity is still difficult in CR. The nephrotoxicity of CyA is
partially explained by a tubulotoxic effect. Therefore, we performed
sequential studies in 18 CR treated with CyA only before and after
conversion to prednisolone (P) and azathioprine (A) (group I), in six
recipients of a kidney from a living, related donor (group 2) treated with
P and A, and in six patients with normal renal function treated with CyA
because of neurological or ocular disease (group 3). The clearances of
'251-iothalamate, '311-hippurate and 99mTcDM5A were measured simul-
taneously. In this way, glomerular filtration rate (GFR), effective renal
plasma flow (ERPF), and DMSA ratio could be determined. In group 1,
values at the time of the lowest GFR before conversion were compared
with values 6 weeks after conversion. Group 2 was studied after
stabilization of the GFR. In group 3, the measurements were carried out
1,2, and 4 weeks after the start of the CyA therapy, and thereafter on
indication. Six CR without rejection episodes showed a different DMSA
ratio before conversion, if compared with the 12 CR with one or more
rejections (0.17 vs. 0.24, normal value being <0.15; P <0.02). The FF
was 0.19 vs. 0.15 (NS), normal value being > 0.18. After conversion,
significant falls in the DMSA ratio were observed to 0.14 and 0.20,
respectively. The difference between the latter values was significant
again (P < 0.02). FF increased in all 18 patients. After stabilization of
the GFR in group 2, a normal DMSA ratio and a normal FF were found.
In group 3, an increase in FF was observed 1 to 2 weeks after the start
of CyA as a result of a decrease in ERPF. Later on, a decrease in GFR
was noted also, but the DMSA ratio remained normal. Bsaed on the
findings in groups 2 and 3, we conclude that the low FF and the high
DMSA ratio in 12 patients of group I was due to rejection and not to
CyA toxicity. Thus, the DMSA ratio is a more sensitive indicator of
rejection than the FF.
Carpal tunnel syndrome in dialysis patients. No evidence for
amyloidosis. J, Bommer, R. Waldherr, K. Andrassy, and E. Ritz.
Departments of Internal Medicine and Pathology, University of
Heidelberg, Heidelberg, Federal Republic of Germany. Deposition of
amyloid was reported in 2 to 8% of patients with idiopathic carpal
tunnel syndrome (CTS) of non-uremic patients. Deposition of amyloid
was reported by several authors in most or all patients on maintenance
hemodialysis with CTS. We can confirm a high prevalence of CTS in
long-term hemodialysis patients. Careful studies of material obtained at
surgery in six patients never did reveal amyloid. Material was examined
after Congo red or crystal violet stains, respectively. The characteristic
green birefringency was never observed; in six cases with unspecific,
slight birefringency, AL-related amyloidosis and light chains-related
amyloidosis could be excluded by appropriate immunofluorescence
studies. Senescent collagen fibers or degraded elastin fibers may also
have the appearance of non-branching fibrils in transmission electron
microscopy, which can be mistaken for amyloid. Our anecdotal obser-
vations do not exclude the possibility of amyloid deposition in long-
term hemodialysis patients. However, this must be a very rare event
indeed, given negative results in six consecutive patients examined with
appropriate techniques.
Immune status in patients on maintenance hemodialysis. P. Kurz, H.
Köhler, T. Hütteroth, M. Weber, and K. H. Meyer zum Buschenfelde.
Department of Internal Medicine, University of Mainz, Mainz, Federal
Republic ofGermany. Uremia has been considered "nature's immune
suppressive device". Many conflicting results have been presented in
recent years concerning the immune status in patients with end-stage
renal failure showing a normal, reduced, or even an enhanced immune
response in patients with chronic hemodialysis treatment. In an earlier
study, we found that the response to hepatitis B vaccine in uremic
patients was slower and weaker than in healthy controls, with only 56%
of the immunized patients producing antibodies against the HBs antigen
(responder). The purpose of the present study was to examine the in
vitro immune response of peripheral blood lymphocytes from uremic
patients compared to normal controls. Peripheral blood lymphocytes(PBL) were differentiated into T4- and T8-positive cells by im-
munofluorescence technique with monoclonal antibodies. PBL were
stimulated with concanavalin A, pokeweed mitogen, phytohemag-
glutinin, and allogeneic cells. Blast transformation was measured by
incorporation of 3H-thymidin into the DNA of the cells. lgG production
in vitro was determined by stimulation of PBL with PWM for 7 days and
measuring IgG concentration by ELISA. Supernatant of stimulated
cells was examined for its IL-2 concentration. Uremic patients had a
marked lymphopenia (1466 cells/sl) with a reduced number of T4- and
T8-positive cells (52.4 and 25.8%, respectively). T4/T8 ratio was 1.93
and within the normal range. Blast transformation was significantly
reduced in uremic PBL. Proliferation index was 12.0, 37.0, 12.8 and 8.3
712 Abstracts
for stimulation with Con A, PHA, PWM, and allogeneic cells, respec-
tively, vs. 45.8, 85.6, 24.1, and 22,7 in healthy controls. Normal PBL
produced IS times more tgG when stimulated with PWM than did
uremic cells. A tendency for a diminished IL-2 production in vitro was
found, but this difference was not statistically significant. The reduced
immune response after hepatitis B vaccination and the presented in
vitro results indicate that there is a profound immune defect in uremic
patients. Probably, this defect is located on the T lymphocytes.
Vaccination policy in patients with renal failure. J. Bommer, M.
Grusendorf, W. Jug, F. Deinhardt, G. Darai, and E. Ritz. Department
of Internal Medicine and Institute of Medical Virology, University of
Heidelberg, Heidelberg, and Max v. Pettenkofer Institute, University
of München, Mflnchen, Federal Republic of Germany. Impaired anti-
HBs formation in vaccinated hemodialysed patients raised the following
questions: I) Does more frequent hepatitis B vaccination improve the
antibody response in patients with renal failure; 2) Are maximal values
and time course of anti-HBs predictive of need for recall vaccination;
and 3) What is the optimal time for vaccination, that is, the time onset
of hyporesponsiveness. Staff (N = 42) and patients with incipient renal
failure (N = 20, creatinine 1.5 to 3 mg%) received 20 g HB-Vax®,
MSD Co. at month 0, I, and 6. Dialysis patients received 40 sg
HB-Vax® either at month 0, 1, 6 (group 1, N = 28) or at month 0, 1, 2,
4, and 6 (group II, N = 23). Anti-HBs: Abbott RIA. Seroconversion
rate and anti-HBs concentration (median, lU/liter) are given in the
table.
8 months 12 months 24 months
Staff 38/42 (91%) 37/42 (88%) 34/42 (81%)
3 x 20 g 333 (4.2 to 14112) 100 (2.7 to 4000) 52(2.4 to 3940)
HD I 15/28 (54%) 14/28 (50%) 5/28 (18%)
3 x 20 g 338 (2.6 to 509) 30.5 (2.0 to 323) 4.2 (3.1 to 34)
HD II 15/23 (65%) 14/23 (61%) 11/23 (48%)
5 x 40 tg 388 (3 to 8516) 76.5 (2.4 to 192) 125 (6.3 to 929)
After 2 years, only 10% of staff had lost their anti-HBs in contrast to
66% of thrice vaccinated and 26% of patients five times vaccinated. The
frequency of anti-HBs loss correlated with the height of maximal
anti-HBs titer. 15/17 patients who lost anti-HBs during 2 years had a
maximal anti-HBs titer below 100 lU/liter. The increase of anti-HBs
titers in hemodialysis patients during the second year is comparable
with exposure to HBV, for example, during holiday dialysis. Patients
with incipient renal failure showed lower seroconversion rates
(65%)than staff (91%), but comparable anti-HBs titers. Both conversion
rate and anti-HBs titers were higher, however, than in hemodialysed
patients vaccinated with double dose. Conclusion: In hemodialysis
patients, more frequent vaccination induces higher maximal titers and
longer persistence of anti-HBs. If anti-HBs titers are below 100 lU/liter,
it is recommended to control anti-HBs every 6 months and/or give a
booster injection. In patients with incipient renal failure, anti-HBs
formation is impaired also.
Different in vitro generation of C3d by duprophane and polycarbon
capillary hemodialysis. M. S. Notohamiprodjo, K. Andrassy, U. Rother,
J. Bommer, and E. Ritz. Departments of Internal Medicine and
Immunology, University of Heidelberg, Heidelberg, Federal Republic
of Germany. Cellulosic membranes have been shown to activate C3 via
the alternate pathway. In the present study, we compared generation of
the stable C3 product, C3d, in an in vitro recirculation system using
either cuprophane (CU) or polycarbonate (PC) hollow fiber minidialyz-
ers with identical geometry. The dialyzers (500 fibers, 0.1 m2, 40 ml
system-priming volume) were rinsed and degassed. Aliquots of heparin-
ized (1 U/mI) platelet pure plasma were recirculated in CU and PC
minidialyzers, respectively (recirculation rate 20 mI/mm). Repeated
samples were taken for C3d measurements with immunoelectrophoresis
after Brandsiund (preadsorption with anti-C3c). After 120 mm, the
system was rinsed with 5 vol saline. No protein (Lowry) was demon-
strable in the fifth wash. The residual protein was washed out (reverse
transmembrane pressure of 1.5 bar, air-filled dialysate compartment)
and analyzed both with flat bed polyacrylamide gel electrophoresis and
with Laurell's technique. Secondary membrane on CU and PC con-
sisted of plasma proteins in relation to their blood concentrations
without selective adsorption (verified for several serum proteins with
Laurell's technique using monospecific antibodies). Time-dependent
increase of C3d in fluid phase as evidence of complement activation was
found in six of eight experiments. C3d increase was less with PC than
with CU. The observation documents alternate pathway activation of
C3 with PC, in contrast to previous in vivo reports. However, C3
activation with PC was less intense than with CU.
